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Abstract
  
Ever since the discovery of cisplatin by Rosenberg in the 1970’s metal complexes 
as anti-cancer drugs have become an increasing subject of research. Ruthenium as a 
substitute for the toxic platinum metal has received a lot of attention recently. 
Organometallic compounds such as arene ruthenium complexes are very versatile and 
have proven to be active against cancer cells. In order to exploit their activity this work 
consisted in incorporating arene ruthenium compounds in large systems for facilitating 
transport into cancer cells. 
 
In a first approach, arene ruthenium compounds were combined with dendritic 
systems to form metalla-dendrimers: The goal of this being to transport the active 
ruthenium compounds into cancer cells by large dendrimers. The biological activity was 
measured which revealed that these complexes are taken up by cells, showing moderate 
to high cytotoxicity. 
 
In a second approach, as arene ruthenium complexes are also interesting 
supramolecular building blocks, supramolecular rectangles were constructed. The 
rectangles are tetra-cationic and slightly water soluble. These discrete supramolecular 
assemblies show moderate to high cytotoxicity depending on the properties of the 
building blocks used. 
 
In a third approach, supramolecular triangular prisms were investigated. The 
prismatic structures can encapsulate large planar compounds. Studies showed that the 
encapsulated compound can not escape the prismatic cage unless it breaks. This property 
can be useful for drug transport, therefore a series of functionalized pyrenyl derivatives 
were encapsulated in the prism. Even though the prism itself is moderately cytotoxic, the 
activity was found to increase with some of the encapsulated pyrenyl derivatives. 
Fluorescent studies were made on the encapsulated 1-(4,6-dichloro-1,3,5-triazin-2-
yl)pyrene. The study agrees with the theory that these complexes are taken up by the cell 
and then, like a Trojan horse, breaks to release the encapsulated species trapped inside. 
 
Keywords 
Arene ruthenium complexes, supramolecular assembly, Trojan horse, anti-cancer 
activity, pyrene, supramolecular prism, supramolecular rectangle, metalla-dendrimer, 
EPR effect.  
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1. Metals in Medicine 
 
1.1 The very beginning 
 
The medically beneficial effects of metals have been explored for centuries. In 
ancient China dating back to about 2500 BC gold was used to treat small pox, skin ulcers 
and furuncles [1]. In ancient Rome the wealthy put silver coins in containers for water 
storage to prevent spoiling due to silver’s anti-bacterial property. Since then metals have 
been used more and more extensively. A metal containing blockbuster medicine called 
Salvarsan was commercialized at the beginning of the 20th Century [2]. The arsenic 
containing Salvarsan was the result of the pioneering work of Paul Ehrlich, who screened 
a library of compounds to find a treatment for syphilis. Even though metals have been 
successfully employed for medicinal purposes in the past, the approach is still 
serendipitous and not many rationally designed metal containing drugs have found the 
market. The major part of industry still focuses on classical drugs built on a carbon 
framework. Transition metals are different, often of octahedral geometry, and could 
therefore produce molecules of different properties, impossible to obtain from a carbon 
framework. Moreover, the solubility could be fine tuned depending on the metal and the 
ligands used. There is alas a branch of rationally designed pharmaceuticals yet to be 
explored. 
 
 
1.2 Cancer therapy: an enormous task  
 
Cancer is one of the greatest threats to humans in the western world, in the U.S. 
and Europe almost 25% of all deaths are caused by cancer, being second only to heart 
diseases as a cause of death [3]. According to statistics it has been predicted that 1 in 3 
men and 1 in 4 women in Europe will be directly affected by cancer before they are 75 
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years old [4]. Alas the numbers are grim although after a peak around 1991 they are 
decreasing, both cancer incidence and death, especially cases of lung cancer has 
diminished. This might be due to better information and habits of the population but that 
is only the author’s speculations.  
 
Cancer as such is not one single disease but a collective name of mutated cells 
that grow uncontrollably. As there are over 50 oncogenes and the types of cells affected 
differ from each case, just one general treatment for cancer as such is difficult. What 
cancer cells do have in common is rapid cell division, because of this, DNA has been the 
target for chemotherapy as this will affect cancerous cells more than normal ones. In 
general in cancer treatment the tumorous tissue is removed by surgery followed by 
treatment with drugs and radiotherapy to remove the last traces of cancerous cells, but as 
mentioned this depends on the cancer type. 
 
The greatest challenge in designing anti-cancer drugs is selectivity. As anti-cancer 
drugs are in general cytotoxic, they are also a threat to normal cells which is why side 
effects are often severe. With massive research focusing on cancer the discovery of 
specific targets in cancer cells has been made: Specific proteins, often protein kinases, 
and growth factors being upregulated, such as epidermal growth factor receptor (EGFR), 
vascular endothelial growth factor (VEGF). With these types of localized targets, drugs 
can be developed to be very selective towards these signaling pathways. This is called 
targeted chemotherapy and some highly selective compounds have been produced such 
as Sunitinib, specific for metastatic renal cancer [5].  
 
A slight problem with targeted chemotherapy lies in the specificity, as there are 
many types of cancer a specific drug will have to be developed for each, a time 
consuming process. In the meantime classical chemotherapy will have to suffice, and 
possibly be improved beyond the need of specifically targeted drugs. 
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1.3 Cisplatin a salvation? 
 
The serendipitous discovery of cisplatin or cis-dichlorodiamineplatinum(II) was a 
great discovery for cancer therapy, and inorganic chemistry as well for that matter. 
Barnett Rosenberg was studying the effect of electric current on E. Coli in different 
media. When these tests were done in medium containing ammonia an elongation of E. 
Coli was taking place. It was later discovered that it was due to release of platinum from 
the electrodes reacting with ammonia that lead to this phenomenon [6]. From this 
discovery cisplatin was developed, being among the most active of the platinum 
compounds tested so far. 
 
 
 
Figure 1. The two isomers of dichlorodiamineplatinum(II) 
 
Cisplatin is a square planar complex, and thus there is another isomer, transplatin 
(Figure 1). Cisplatin is several orders of magnitude more active than transplatin due to its 
mode of action in the cell. It is widely believed that cisplatin slowly hydrolyzed to 
produce an aqua species which in turn reacts with the base pairs of DNA, binding two of 
them covalently to produce a kink in the DNA [7]. If enough platinum is bound without 
repair the cell will die through apoptosis.  
 
Cisplatin was approved for clinical use in 1978 and together with its derivatives 
have been used readily in chemotherapy ever since being deployed in about 60% of 
cancer cases [8]. Even though commonly used and effective, cisplatin suffers from 
several problems. It has a high general toxicity, not being very selective for cancer cells, 
and as a result inflicts severe adverse effects like neurotoxicity and nefrotoxicity. In 
addition cisplatin also suffers from resistance mechanisms [9]. This has induced massive 
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research in platinum compounds to improve these problematic features [10-15]. Even 
though thousands of compounds have been produced only a few have reached clinical 
trials and only two have been approved worldwide, carboplatin and oxaliplatin (Figure 2). 
Even though some of the problems were diminished with the introduction of carboplatin 
and oxaliplatin on the market some still resides and it remains an active field of research.  
 
Figure 2. Platinum drugs carboplatin and oxaliplatin 
 
 
1.4 Ruthenium as a substitute 
 
Ruthenium compounds as biologically active agents have been evaluated in the 
1950’s by Dwyer and co-workers [16]. They studied the effect of several inorganic 
ruthenium complexes on bacteria and mice. However these studies did not appeal to the 
rest of the scientific world and were largely forgotten. After the success of cisplatin and 
the discovery of its shortcomings, a branch of scientist started to look into the possibility 
to interchange the toxic platinum with other metals. The interest for ruthenium has 
increased and it has become a strong candidate for several reasons: It is less toxic in 
general than platinum [8, 17-18]; it possesses an exchange rate of the chloride ligand 
similar to platinum compounds which is important for biological applications; moreover 
ruthenium has a wider range of oxidation states available and can mimic iron, thus 
profiting from natural transport mechanisms in the body. The latter may be an 
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explanation to the selectivity for cancer cells exhibited by ruthenium compounds as 
cancer cells have a higher uptake of iron due to their rapid proliferation.  
 
 
1.4.1 Inorganic ruthenium compounds 
 
The most successful ruthenium compounds so far are inorganic Ru(III) 
complexes. After the success of cisplatin, cisplatin analogs of ruthenium such as tetra 
amine dichloro ruthenium complexes were tested in the pioneer work of Clarke et al. [19-
20]. The major drawback with these compounds was their poor water solubility which is 
essential for biological applications. A method to introduce water solubility is to make 
charged complexes. This has been applied in the work of Sava and Keppler. Sava’s 
compound NAMI-A is based on an imidazole and a DMSO ligand while Keppler’s 
KP1019 compound contains two indazole ligands (Figure 3).  
 
 
Figure 3. Ruthenium compounds in clinical trials, NAMI-A [21] and 
KP1019 [22] 
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NAMI-A was developed from ruthenium DMSO type compounds, it is not very 
active against primary tumors but possesses high anti-metastatic activity. In contrast to 
cisplatin, NAMI-A only binds weakly to DNA, so it’s activity is from another mechanism 
yet not clear [21]. KP1019 on the other hand is more stable and has high anti-tumoral 
activity but is not anti-metastatic [22]. It is believed that Ru(III) species are reduced to 
Ru(II) by reducing agents inside the cancer cells and that Ru(II) is the active species. 
Both NAMI-A and KP1019 has successfully completed phase I clinical trials [23-24], 
this brings hope in the future for ruthenium chemistry in the pharmaceutical domain. 
 
 
1.4.2 Organometallic ruthenium compounds 
 
Arene ruthenium complexes are an organometallic class of compounds that have a 
face capped arene bound through the π-system to the metal in an η6 fashion stabilizing 
the Ru(II) oxidation state, this creates a piano-stool type complex with the arene as a seat 
and three σ-ligands (XYZ) as legs (Figure 4). 
 
      
Ru
R
ZY
X
 
Figure 4. Arene ruthenium compound (piano-stool complex) 
 
The hydrophilic nature of the metal and the hydrophobic nature of the arene 
ligand dawn for a versatile complex. The arene can be functionalized with many types of 
groups [25] and in addition the σ-ligands can be tuned for solubility or chosen to achieve 
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charged complexes to increase solubility in water. Moreover being already in Ru(II) 
oxidation state, these compounds do not need to be activated by reduction. Arene 
ruthenium compounds were developed as anti-cancer agents by the groups of P. J. Sadler 
[26] and P. J. Dyson [27]. The mechanism of this type of complex is still not completely 
clear but it is believed that similarly to cisplatin the complex is hydrolyzed in the cell and 
binds to DNA most favorably to the N7 of guanine [28]. The corner stone compound 
from Dyson and co-workers is RAPTA-C (Figure 5) from which derivatives have been 
made, in general derivatizing the arene moiety and having pta (1,3,5-triaza-7-phospha-
adamantane) as one of the σ-ligands [8]. The typical arene ruthenium complexes from 
Sadler and co-workers is [(η6-biphenyl)Ru(en)Cl]+ (Figure 5), which possesses a large 
hydrophobic arene and a chelating σ-ligand, thus affecting the rate of hydrolysis of the 
remaining chloro ligand which seems to be an important factor for biological activity. It 
is important that the complex is hydrolyzed inside the cell to be active, these complexes 
rely on the higher concentration of chloride in blood plasma, that by equilibrium hinders 
the hydrolysis from taking place [29-30]. 
 
Figure 5. Typical arene ruthenium compounds, RAPTA-C [8] and [(η6-
biphenyl)Ru(en)Cl]+ [29-30] 
 
Another approach to create active arene ruthenium compounds is by using 
multinuclear complexes. Trinuclear arene ruthenium clusters (Figure 6A) have proven to 
be surprisingly active, having activity 5 times less than cisplatin but 20-30 times more 
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active than most arene ruthenium complexes [31]. The arenes of the cluster can be 
interchanged with the same wide variety as general arene complexes, this is important to 
fine tune solubility and possibly attach biologically active groups. The novelty in these 
complexes lies in the metal-metal bond which is quite rare in this domain and it can also, 
being large, target the EPR effect (enhanced permeability and retention) which will be 
discussed in detail in Chapter 2. 
 
Multinuclear arene complexes can also be in the form of arene complexes 
connected by an organic linker like in the work of Hartinger and Nazarov [32]: The linker 
being a maltol derivative connected by an aliphatic chain that binds to the ruthenium as a 
bidentate ligand (Figure 6B). They studied structure activity relationships (SAR) and 
came to the conclusion that the length of the linker seems to correlate to activity, 
probably due to the change in lipophilicity. These complexes were found to bind to DNA 
and some proteins and were even more active against two oxaliplatin resistant cell lines 
than native cancer cell lines [33]. 
 
Figure 6. Multinuclear arene ruthenium complexes, A: trinuclear arene 
ruthenium cluster [31], B: binuclear arene ruthenium complex connected 
by linkers [32] 
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Another example, but of different purpose, is the metalla-porphyrins investigated 
by Therrien and co-workers. It is a porphyrin scaffold with pyridine rings that binds four 
arene ruthenium moieties (Figure 7). These were developed for photodynamic therapy 
(PDT) i.e. compounds that are relatively inactive in the dark and can accumulate in 
cancerous tissue but activated upon irradiation with light. These proved to be strong 
candidates as in the dark they were not toxic (IC50 > 80 μM), while when irradiated they 
were highly cytotoxic. The utility of the arene ruthenium moiety was proven as the 
Cp*Rh (Cp* = pentamethylcyclopentadienyl) analogue was not internalized by cancer 
cells [34-35]. Apparently the arene ruthenium plays an important role to solubilize and 
induce more selective transport into cancer cells for these systems. 
 
Figure 7. Arene ruthenium metalla-porphyrins [34-35] 
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2. Drug Transportation 
 
In drug design, one of the problems encountered is to ensure delivery of the drug 
to its target. In general, drugs are given orally and they have to pass a number of 
biological systems with harsh conditions, stomach and liver for example, in which they 
might need protection. Intravenous drugs avoid some of these limitations except for the 
fact that it has to be given by authorized personnel. Most drugs, depending on their target, 
have to be water soluble enough to be transported with the blood stream but also 
lipophilic enough to pass cell membranes and other barriers. Drugs also need to be 
somewhat specific to their target, a large number of attributes for a single compound. To 
improve attributes without designing a new drug, delivery by another compound or 
vector, hidden inside, grafted on the outside or even connected to biomolecules is quite 
attractive. This changes the biodistribution and clearance of the molecule significantly 
and drugs which are effective but otherwise sensitive to biomolecules can be used. 
 
 
2.1 The enhanced permeability and retention effect 
 
Nowadays, research concentrating on putting a large amount of drugs inside or 
onto large molecules or other systems shows great promises: The reason being the 
enhanced permeability and retention (EPR) effect of cancer cells. Described by Y. 
Matsamura and H. Maeda in the 80’s when they realized that a polymeric protein was 
more active than the single product [36]. They came to the conclusion that this effect 
depends on the special vascular and lymphatic properties of cancer cells. Cancer cells are 
growing rapidly. They are in higher demand of nutrients for cell division than normal 
cells. Because of this need of nutrients, the vascular endothelial growth factor (VEGF) is 
expressed to induce angiogenesis (create new blood vessels to the tumor cells) which 
increases the permeability of the cell membrane. The increased permeability leads to a 
higher uptake of large molecules and proteins. However the major difference from 
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normal cells resides in the lymphatic drainage, which is severely impaired for cancer 
cells, thus leading to the retention of large molecules and lipids inside the cell [37]. This 
is an excellent target for the development of anti-cancer agents: Large molecules would 
almost selectively be taken up by cancer cells and as well retained inside these disease 
cells whereas if uptaken in normal cells excretion through its healthy lymphatic system 
might occur. 
 
 
2.2 Metal drug delivery 
 
With the discovery of potential delivery systems and the EPR effect, attempts to 
include anti-cancer metal-based drugs in transport vectors have been made. Naturally 
most attempts have focused on platinum compounds as they are clinically used, very 
effective but not selective. Therefore, this transport strategy could be a method of 
increasing efficacy and selectivity. 
 
 
2.2.1 Dendrimers as drug delivery vectors 
 
Dendrimers can be well controlled in size unlike other polymers. At higher 
generation they take on a stable globular shape, similar to many biomolecules, and have a 
tight outer shell. This has made them interesting for biological applications as they are 
more stable than micelles and lipid bi-layers as transport vehicles [38] and can target the 
EPR effect. Inside the solid outer shell of dendrimers, cavities of different sizes which 
can accommodate drugs, are used for transport. Moreover drugs can also be connected to 
the outer shell via binding to the end-groups of the dendrimer. Duncan et al. reported the 
conjugation of cisplatin to a polyamido amine (PAMAM) dendrimer, modified on the 
periphery with sodium carboxylate functionalities (Figure 8) [39]. The dendrimer-
platinate is water soluble and displayed anti-tumor activity when administered 
12 
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intravenously against a B16F10 melanoma, whereas cisplatin was inactive. Dendrimers 
are nowadays commercially available and incorporation of drugs and diagnostic agents is 
a hot topic. 
 
Figure 8. Cisplatin conjugated to PAMAM dendrimer, one branch of a 
greneration 3.5 dendrimer synthesized by Duncan [39] 
 
 
2.2.2 Carbon nanotubes 
 
Carbon nanotubes are tubular carbon frameworks that have recently received 
attention because of their ability to travel across cell membranes [40-42]. This has lead to 
research with the goal to incorporate drugs inside their cavity for transportation. Single 
wall nanohorns (SWNHs) filled with platinum compounds, which cluster together to give 
large spherical structure has proven to increase activity of cisplatin (Figure 9) [43].  
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Figure 9. Cisplatin inserted into SWNH which then cluster into spherical 
aggregates [43] 
 
Single wall nanotubes (SWNTs) have been functionalized by covalently tethered 
platinum compounds. The toxicity towards testicular cancer was increased with up to 25 
fold of the parent complex (Figure 10) [44]. However they were taken up by the cell 
through an endocytotic process and did not target the EPR effect. It still proves that these 
systems, although biologically unorthodox, can be used as transport vectors. 
 
O O O
O O
Pt Pt Pt
PtPt
ClH3N
OEt
ClH3N
ClH3N
OEt
ClH3N
ClH3N
OEt
ClH3N
H3N Cl
ClH3N
OEt
H3N Cl
ClH3N
OEt
 
Figure 10. SWNT with tethered platinum compounds [44] 
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2.2.3 Liposomes 
 
Liposomes are spherical structures made up of a lipid bi-layer and an aqueous 
core (Figure 11). They form spontaneously in aqueous solution by lipids having 
hydrophobic tails and hydrophilic heads. They can be loaded with drugs and target the 
EPR effect by being large and retained in the cell because of their lipid nature. However 
cisplatin was not successfully loaded into these systems as it is not lipophilic enough, 
thus more lipophilic derivatives like Aroplatin (Figure 11) were made and eventually 
successfully loaded into the bi-layer. The effects were positive and a system like this is in 
phase II clinical trials [45].  
 
Figure 11. Cross section of a liposome with Aroplatin loaded into the bi-
layer [45] 
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2.2.4 Large systems which do not target the EPR effect 
 
Even though the EPR effect is an attractive target not all drug delivery systems 
focus on this opportunity. Indeed the macrocyclic system cucurbit[n]uril (Figure 12A) 
protect highly active platinum compounds that would otherwise be deactivated before 
reaching their target (Figure 12B).  
 
Figure 12. A: Cucurbit[n]uril, B: Insertion of a dinuclear platinum 
complex into a cucurbit[7]uril [46-47] 
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They also prevent resistance from the glutathione protein mechanism [46-47]. 
Incorporation in ceramic materials has been investigated for slow release close to the 
tumorous tissue. Another system is incorporation into or onto biomolecules which are 
large but taken into the cell by endocytosis and not through the membrane. These are in 
general equipped with antibodies or receptors to target cancer cells specifically [48]. 
 
 
2.3 Goals of this project 
 
Even though drug delivery vectors are well known, a supramolecular approach 
remains rare. Discrete supramolecular assemblies are versatile and their charge and 
solubility can be controlled, moreover there is a possibility for host guest chemistry 
which can be used for transport and release of drugs. Arene ruthenium compound have, 
as mentioned, received a lot of attention for their biological activity, and in recent years 
as well for the possibility to use them as supramolecular building blocks. Discrete 
systems are as well advantageous in medicinal chemistry as they are well defined.  
 
This work has aspired to investigate the versatility of arene ruthenium chemistry, 
incorporating them into large systems like discrete supramolecular assemblies and 
dendrimers. Making such compounds renders large water soluble systems, an important 
factor for biological activity making them bio-available. The presence of several metal 
centers should give high activity and may give rise to selectivity as ruthenium 
compounds have shown some selectivity for cancer cells. Moreover it is possible to 
encapsulate hydrophobic species in discrete supramolecular assemblies; this could serve 
as a drug delivery system for drugs with low solubility. As these systems are large 
selectivity might be increased if the enhanced permeability and retention (EPR) effect can 
be exploited. 
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3 Dendritic Systems 
 
3.1 Introduction 
 
Arene ruthenium complexes are air stable, soluble and versatile organometallic 
compounds that defy the notion that organometallic compounds are air and moisture 
sensitive. They are prepared in a dimeric form from the reaction of RuCl3 with a cyclic 
diene, first synthesized by Winkhaus and Singer in 1967 [49]. However the structure was 
thought to be in polymeric form and the dimeric form was not discovered until later by 
Baird [50] and Bennett [51]. The chloro-bridged dimeric species formed can easily be 
broken up by the addition of a ligand (L) (Scheme 1).  
 
Scheme 1. General synthesis of arene ruthenium complexes 
 
Some arene ruthenium dimers cannot be obtained through the reaction of RuCl3 
with the corresponding diene as electron rich systems like hexamethylbenzene and 
durene can not be reduced to dienes. However the arene ruthenium dimer can be obtained 
from an arene exchange reaction by reacting the p-cymene dimer with the aromatic 
system at high temperature (Scheme 2) [51].  
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Scheme 2. Arene exchange reaction of p-cymene with hexamethylbenzene 
 
As previously mentioned arene ruthenium complexes have recently caught 
attention as biologically active agents, mostly for anti-cancer activity. 
 
Dendrimers are a polymer class of compounds which are highly branched starting 
from a core. They are synthesized by two methods, the divergent and the convergent 
method: The divergent method being the first introduced by Tomalia and co-workers 
[52], starting from the core adding branching segments outwards (Figure 13A), each layer 
of branching segment being called a generation (G). In the convergent method, developed 
by Fréchet and co-workers [53], the synthesis starts from the end groups, then connecting 
the branching segments inwards and connecting the large segments to the core in the final 
step (Figure 13B). 
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Figure 13. Divergent (A) and convergent (B) methods to prepare 
dendrimers [38] 
 
In order to exploit size selective uptake of drugs into tumor cells effectively, large 
compounds are required, and in recent years, dendrimers have found potential as 
molecular tools in biological applications [54-56], especially as nano-carriers [57], 
diagnostic agents [58] and as chemotherapeutics [59-61]. Moreover, another advantage of 
dendrimers is their multivalency, which leads to increased interaction between a 
dendrimer-drug conjugate and a target bearing multiple receptors, further improving the 
selectivity to cancer cells. With the aim of reducing the inherent problems related to 
cisplatin such as poor water solubility, high toxicity and side effects, the combination of 
platinum-based drugs with dendritic systems is very appealing. However, transition metal 
complexes with anti-cancer activity, based on a dendritic scaffold are quite rare. Using 
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the commercially available butanediamine poly(propyleneimine) dendrimer (DAB(PA)4) 
(Figure 14) which provides four peripheral amine groups a series of tetranuclear platinum 
compounds were synthesized.  
 
The cationic compound [DAB(PA)4{Pt(NH3)2Cl}4]4+ was designed to overcome 
cisplatin resistance [62], while the neutral derivative DAB(PA)4{Pt(dmso)(L)}4 (L = 
meso-1,2-bis(4-fluorophenyl)ethylenediamine) was prepared to increase selectivity for 
breast cancer cells [63]. With the established anti-cancer activity of arene ruthenium 
complexes and the current interest in dendrimers for biological applications, we decided 
to explore the synthesis of multinuclear ruthenium complexes based on a 
poly(propyleneimine) scaffold and investigate their cytotoxicity against A2780 human 
ovarian cancer cell line. 
 
As far as we are aware these studies are the first to exploit arene ruthenium 
compounds using this approach although tumor targeting of arene ruthenium compounds 
via covalent attachment to recombinant human serum albumin via a pH cleavable linker 
has been reported [64]. 
 
Figure 14. Second generation of a DAB dendrimer 
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3.2 Synthesis and characteristics 
 
3.2.1 Synthesis and characterization of iminopyridyl-functionalized dendritic 
ligands G1 and G2  
 
In collaboration with Dr Gregory Smith and co-workers at the University of Cape 
Town (South Africa) a first- (G1) and second-generation (G2) iminopyridyl dendrimer 
based on a poly(propyleneimine) scaffold were synthesized via a standard Schiff-base 
reaction. The 4-pyridylimine-functionalized dendritic ligands (G1–G2) were prepared by 
the reaction of 4-pyridinecarboxaldehyde with DAB-(NH2)n (n = 4, 8 for G1 and G2, 
respectively) (Scheme 3). The dendritic ligands are isolated as orange-yellow oils, in 
moderate yields. They are soluble in dichloromethane, chloroform, methanol, diethyl 
ether and tetrahydrofuran.  
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Scheme 3. Synthesis of iminopyridyl dendrimer G1 (top) and G2 (bottom) 
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The Schiff base condensation reaction is confirmed by appearance of a peak in the 
range 8.17 and 8.23 ppm assigned to the imine protons for G1 and G2, respectively. Two 
distinct doublets (3J ~ 6.00 Hz) are observed for the aromatic protons on the 4-pyridyl 
rings. 13C{1H} NMR spectra for both ligands (G1–G2) show similar signal patterns. 
Aliphatic carbons were seen in the region of 25–60 ppm and aromatic carbons in the 
region of 120–150 ppm for both generations. As expected for both ligands the imine 
carbon was the most deshielded signal at 159 ppm. For both G1 and G2, the IR spectra 
show two absorption bands of strong intensity at ~1647 and 1599 cm-1 assigned to the 
(C=N) imine and (C=N) aromatic vibrations respectively. 
 
 
3.2.2 Synthesis and characterization of metalla-dendrimers 
 
 The dinuclear arene ruthenium complexes [(η6-arene)RuCl2]2 (arene = p-cymene, 
hexamethylbenzene) react with the dendritic ligands G1 and G2 at room temperature in 
dichloromethane to yield the neutral tetranuclear (1-2) (Figure 15) and octanuclear (3-4) 
(Figure 16) ruthenium metalla-dendrimers. The yellow-orange solids (1-4) are isolated as 
air-stable solids in high yields (79-98%). The complexes are soluble in most organic 
solvents such as dichloromethane, chloroform, ethanol, dimethylsulfoxide, acetone, 
acetonitrile, diethyl ether and tetrahydrofuran.  
24 
  Dendritic Systems   
 
Figure 15. Metalla-dendrimers G1, tetranuclear 1-2 
 
 
Figure 16. Metalla-dendrimers G2, octanuclear 3-4 
  25  
Dendritic Systems 
The 1H NMR spectra of 1-4 shows broadened peaks upon complexation of the 
multinuclear ruthenium moieties. The aliphatic protons of the dendritic core and side 
arms occur at similar shifts to those of the dendritic ligand precursors. Evidence for the 
coordination of the ruthenium metal to the aromatic nitrogen atom can be seen by a shift 
in the doublet (assigned to aromatic protons on the carbon adjacent to pyridyl nitrogen 
atom) from 8.66 to 9.10 ppm. A shift in the signal is due to the electron-withdrawing 
effects of the coordinating metal, resulting in the signals being shifted downfield. There 
is also no distinct shift in the imine proton suggesting no coordination at this position. 
The 1H NMR spectrum for the second generation of complexes (3-4) showed similar 
shifts to the first generation. This alludes to coordination at the pyridyl nitrogen only and 
not the imine nitrogen. This is further confirmed by IR spectroscopic studies. Infrared 
spectroscopic studies show a shift in the (C=N) aromatic peak from a lower wavenumber 
to a higher wavenumber at around 1615 cm-1. The (C=N) imine absorption band remains 
unchanged at around 1646 cm-1. The second generation dendritic complexes show similar 
trends. The ruthenium functionalized dendrimers (1-4) were precipitated with the 
inclusion of solvent, trapped between the dendritic arms. The elemental analysis data 
correlates with the inclusion of 2 molecules and 4 molecules of dichloromethane for 1 
and 3, respectively. 
 
 
3.2.3 Synthesis and characterization of mononuclear compounds 
 
For comparison, the analogous mononuclear ruthenium complexes (5-6) were 
synthesized (Figure 17). These were prepared by reacting the ligand, N-(pyridin-4-
ylmethylene)propan-1-amine (L), with the dinuclear arene ruthenium complexes [(η6-
arene)RuCl2]2 (arene = p-cymene, hexamethylbenzene) in dichloromethane at room 
temperature. The mononuclear ruthenium complexes (5-6) are isolated as yellow-orange 
solids in high yields. They are air-stable and soluble in most solvents. 
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Figure 17. Mononuclear ruthenium compounds 5-6 
 
The aromatic protons adjacent to the pyridyl nitrogen atom appear more 
downfield than for the uncoordinated ligand (8.66–9.10 ppm), while the imine protons 
remain at the same position as for the dendritic ligand (~8.2 ppm). A shift in the (C=N) 
aromatic absorption band in the IR spectrum of 5 and 6 is seen at around 1550–1615 
cm-1. The (C=N) imine absorption band around 1647 cm-1 remains constant and confirms 
that no coordination occurred at this site. The coordination of the ruthenium metal 
occurred to the aromatic nitrogen atom was further confirmed by the X-ray structure 
analysis of complex 5. 
 
X-ray quality crystals for complex 5 are obtained by slow diffusion of hexane into 
a concentrated dichloromethane solution of 5. The molecular structure of 5 shows that, 
like other arene ruthenium complexes [25], the metal center adopts a piano-stool, pseudo-
tetrahedral geometry, with ruthenium coordinated by the arene ligand, two chlorides and 
the iminopyridyl ligand. An ORTEP drawing of 5 is shown in Figure 18 and selected 
bond lengths and angles are presented in Table 1. The distance between the ruthenium 
atom and the center of the C6H4 aromatic ring of the p-cymene ligand is 1.670(4) Å. The 
Ru–N and Ru–Cl bond distances in 5 are comparable to those reported in the pyridine 
(py) derivatives [(η6-1,3,5-trimethylbenzene)RuCl2(py)] [65] and [(η6-
hexamethylbenzene)RuCl2(py)] [66]. Similarly, the Cl–Ru–N and Cl–Ru–Cl bond angles 
of complex 5 [84.8(2) and 87.0(2)] are similar to those in [(η6-1,3,5-trimethylbenzene) 
RuCl2(py)] and [(η6-hexamethylbenzene)RuCl2(py)]. As suggested previously, only the 
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aromatic nitrogen atom is found to be coordinated to the ruthenium atom, thus validating 
the coordination mode proposed in complexes 1-4. 
 
 
 
Figure 18. Molecular structure of the mononuclear complex 5 showing 
ellipsoids at the 50% probability level 
 
 
Table 1. Selected bond lengths and angles of compound 5 
Bond lengths (Å) Bond angles (°) 
Ru(1)–N(1)  2.128(9) N(1)–Ru(1)–Cl(1)  84.8(2) 
Ru(1)–Cl(1)  2.406(3) N(1)–Ru(1)–Cl(2)  87.0(2) 
Ru(1)–Cl(2) 2.405(3) Cl(1)–Ru(1)–Cl(2) 87.6(2) 
N(2)–C(16) 1.34(3) C(13)–C(16)–N(2) 115(2) 
N(2)–C(17) 1.49(3) C(16)–N(2)–C(17) 125(2) 
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3.3 Biological activity 
 
The biological activity was tested in collaboration with Prof. Paul Dyson and co-
workers at the EPFL (Switzerland). The ability of 1-6 to inhibit cancer cell growth was 
evaluated in vitro on A2780 ovarian cancer cell line using the biological MTT assay 
which measures mitochondrial dehydrogenase activity as an indication of cell viability. 
The compounds are incubated at various concentrations (in triplicate) in the A2780 cells 
and cell viability is measured after an incubation period of 72 hours. Each experiment is 
conducted in duplicate and the IC50 values (inhibition of cancer cell growth at the 50% 
level) listed in Table 2 are calculated as an average over two experiments. All compounds 
display moderate anti-proliferative activity in the A2780 cell line. While the IC50 values 
determined are higher than that of cisplatin, the most active compounds, 3 and 4, are 
relatively low for ruthenium compounds.  
 
Table 2. IC50a values for compounds 1-6 measured on A2780 human 
ovarian cancer cell lineb
Compound IC50 (μM) 
1 [{(η6-p-cymene)RuCl2}4G1] 43 
2 [{(η6-hexamethylbenzene)RuCl2}4G1] 40 
3 [{(η6-p-cymene)RuCl2}8G2] 21 
4 [{(η6-hexamethylbenzene)RuCl2}8G2] 20 
5 [(η6-p-cymene)RuCl2(L)] 98 
6 [(η6-hexamethylbenzene)RuCl2(L)] 94 
cisplatin 1.6 
a Concentration at which 50% of cell viability is inhibited. 
b Maximum error is < ± 5 μM. 
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These are the first examples of arene ruthenium dichloro complexes with an 
iminopyridyl ligand to be tested for in vitro activity. However, analogous 
hexamethylbenzene and p-cymene cyanopyridyl complexes have previously been 
reported to show significant unwinding of supercoiled DNA and also inhibit haem 
polymerase activity. In contrast, [(η6-p-cymene)Ru(py)Cl2] was found to show negligible 
activity in the TS/A cell line [67]. There is a clear trend between the size of the dendritic 
compound and cytotoxicity, i.e. the monoruthenium compounds have modest cytotoxicity 
whereas [{(η6-p-cymene)RuCl2}8G2] 3 and [{(η6-hexamethylbenzene)RuCl2}8G2] 4 are 
cytotoxic. Based on this observation, the biological properties of 3 and 4 are worth 
studying further as they may be able to target cancerous tissues more effectively than 
smaller compounds by exploiting the enhanced permeability and retention effect, a 
property that needs to be evaluated in vivo. Moreover, the activity shown here for 3 and 4 
is not too dissimilar to that of the multinuclear arene ruthenium adduct of recombinant 
human serum albumin [57], but the facile synthesis and considerably lower cost of the 
dendrimer system, cannot be overlooked. 
 
 
3.4 Conclusions 
 
A number of metalla-dendrimers have been produced from G1 and G2 organic 
dendrimers in a simple and straightforward synthetic route, producing the final metalla-
dendrimers in high yields. These derivatives were tested for biological activity and found 
to be cytotoxic in comparison to a mononuclear reference compound. The simplicity of 
synthesis and the possibility to target the EPR effect make these compounds favorable for 
further studies. If these compounds really target the EPR effect has yet to be confirmed, it 
might be necessary to compare with higher generations of dendrimers to evaluate a 
potential synergistic effect.  
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4. Supramolecular Rectangles  
 
Arene ruthenium complexes are as mentioned versatile and have been used for 
many purposes. One fairly new approach is to use these systems in supramolecular 
assemblies. Earlier, mostly platinum and other square planar metals centers have been 
used, but arene ruthenium complexes offer an octahedral complex controllable in its 
geometry by the blocking of three ligand sites through the arene ligand. 
 
 
4.1 Introduction 
 
4.1.1 Supramolecular squares, a new dawn in supramolecular chemistry 
 
Self-assembly is a process leading to the formation of discrete nanometer-sized 
objects or well-defined aggregates in which the overall structure is controlled by the 
symmetry of the different building blocks [68-72]. In the case of metalla-supramolecular 
assemblies, the coordination mode of the metal center as well as the symmetry of the 
ligands needs to be controlled in order to allow the formation of the desired aggregates. 
 
Fujita et al. pioneered the usage of 90° building blocks in the 90’s and many other 
groups subsequently followed. Fujita in early experiments used square planar Pd 
compounds with ethylenediamine (en) ligand to block two adjacent coordination sites and 
produce a compound capable of binding bridging ligands in a 90° angle. When these 
palladium corners react with four linear bidentate ligands molecular squares are formed 
(Scheme 4).  
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Scheme 4. Synthesis of the square [{(en)Pd(4,4’-bipy)}4]8+ [73] 
 
The synthesis is thermodynamically controlled and has an equilibrium favoring 
the formation of the square. The cavity can host a guest which was seen by NMR 
spectroscopy upon addition of 1,3,5-trimethoxy benzene in solution [73]. 
 
With these types of systems a new branch of supramolecular chemistry started, 
incorporating dative metal bonds in confined nanosized structures and not large lattices or 
frameworks as earlier metal containing supramolecular structures. These systems consist 
of two types of building blocks, an angular unit that contains two coordination sites or 
bonding possibilities in an angle of choice, and a linear bridging unit with binding sites in 
180° relative orientation. The final shape of the molecule is dependent on these angles. A 
connecting corner with a 60° angle would hence produce a triangle whereas 90° would 
produce a square, 108° a pentagon and 120° a hexagon (Figure 19) when combined with 
linear bridging units [74]. 
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Figure 19. Strategy of producing different shaped 2D supramolecular 
architectures [74] 
 
It is also possible to combine angular units with other angular units to produce 
rhombic shapes, squares and hexagons. Stang et al. investigated several rectangular 
systems and came to the conclusion that there are other forces determining the structure 
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than the angles. The strength of the dative bond has an impact on the formation: This was 
found while trying to synthesize Pt and Pd squares with cyanoligands (Scheme 5). While 
the Pd corners formed the desired squares the Pt counterpart only formed oligomers, due 
to the weaker bond to Pd which allows reconfiguration to the thermodynamically more 
stable product [74-75]. The self-assembly of discrete system relies on equilibrium, if the 
reaction is under kinetic control oligomers will be the main product. However when 
under thermodynamic control the equilibrium of the reaction will allow for multiple 
species to form but ultimately the most stable will naturally be favored. If an assembly is 
broken up or misformed it can thus self repair into the most stable form. This self 
reparation is quite common in natural systems. 
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Scheme 5. The formation of Pt oligomers versus thermodynamic product 
the Pd square [74-75] 
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Another factor that contributes to the stability of the squares is π-stacking, where 
in the case of the compounds in Scheme 5 the phenyl in the biphosphine ligand can 
interact with the bridging ligand. However this interaction is weak in the cynaoligand 
case but much stronger if a 4,4’-bipyridine bridging ligand is used. Stang also showed 
that squares of lower symmetry are obtainable by using two different angular units 
creating bimetallic squares (Figure 20 compound A and B) [76-79], this has as well been 
done by Hupp in a different fashion (Figure 20 compound D) [80]. Fujita created rhombic 
structures by an analogous strategy of combining angular units of different types and 
different angles (Figure 20 compound C) [81]. 
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Figure 20. Bimetallic squares by Stang (A [76-77], B [78-79]) rhombic complex by 
Fujita (C) [81] and bimetallic complex by Hupp (D) [80] 
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Even though this seems like a simple and straightforward strategy for making 
rationally designed supramolecular structures there are some exceptions. Rigid ligands 
combined with 90° metallic corners that form triangular species instead of the expected 
squares. The combination of the small rigid pyrazine (pyz) ligand with a square planar 
complex of rhodium produced the triangular complex [{Rh(PPh3)2(pyz)}3]3+ [82], the 
same results were observed with a similar platinum complex containing pyrazine 
resulting in the triangular complex [{Pt(PEt3)2(pyz)}3]6+ [83].  
 
Alessio and co-workers studied this phenomenon and was the first to produce 
triangles with octahedral metal corners instead of square planar. It was concluded that 
even though the reasons for this formation is not completely known, steric effects of the 
ancillary ligands are important as this narrows the 90° angle and hence makes the triangle 
the more favorable product as the metal-pyrazine bond also is tilted to relieve strain and 
minimize energy loss [84]. 
 
 
4.1.2 Supramolecular rectangles: a challenge 
 
Hupp et al. investigated the possibility of forming molecular rectangles by mixing 
angular corners Re(CO)5Cl with linear bridging ligands of different sizes such as 
pyrazine and 4,4’-bipyridine. Even though it is statistically possible to form a rectangle 
from this mixture, this did not happen, instead they ended up with two different sized 
squares [85]. This implies that it is thermodynamically unfavorable to form asymmetrical 
compounds.  
 
To be able to synthesize supramolecular rectangles a change of strategy is needed. 
A possibility is to make one robust side of the rectangle so that it has two 90° angular 
coordination sites in one unit, this could then be combined with a linear component of 
preferred length (Figure 21).  
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Figure 21. Synthetic strategy to generate supramolecular rectangles 
 
Stang and co-workers developed this strategy, even though a similar approach 
was used by Süss-Fink and co-workers in 1997 [86], they called the compound with the 
two 90° angles a “molecular clip”. The first test with a biphenyl linker between two 
platinum complexes was unsuccessful as the biphenyl rotated and the reactive sites ended 
up on opposite sides. A more rigid anthracene bridge unable to rotate was then developed 
to produce rectangles of various sizes (Figure 22) [87].  
  37  
Supramolecular Rectangles   
 
Figure 22. Synthesis of rectangles via anthracene platinum “molecular 
clip” [87] 
 
 
4.1.3 Half sandwich compounds in supramolecular assemblies 
 
Half sandwich complexes like arene ruthenium compounds have recently become 
interesting building blocks in supramolecular chemistry. Their geometry with three 
coordination sites available at 90° angles is a useful feature in self-assembly. By 
combining bridging ligands with three donor atoms with half sandwich complexes where 
the bridge binds as a bidentate ligand to one metal center and the third donor to another 
metal center, self-assembled macrocycles can be produced. 
 
An early discovery of supramolecular half sandwich structures was one by 
Wolfgang Beck and co-workers who during their work of studying reactions of 
bioligands with RhCp* (Cp* = pentamethylcyclopentadienyl) complexes found that by 
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removing the chloride with Ag+ these compounds formed chiral trimeric supramolecular 
structures (Figure 23) [88].  
 
Figure 23. Synthesis of trinuclear half sandwich structure [88] 
 
As well as trimeric complexes, dimeric, tetrameric and hexameric macrocycles 
are accessible from similar components. Tri, tetra and hexameric structures are all 
accessible using adenine derivatives as a bridging ligand, small changes on the adenine 
derivative determining the final structure. Independent studies by Fish, Sheldrick and 
Yamanari using different half sandwich complexes showed that free adenine (Figure 24, 
A) forms tetramers whereas its ethyl derivative (Figure 24B) forms trimers [89-90]. With 
9-ethyl-hypoxanthine (Figure 24C) a trimeric species is formed [91] while the thio 
derivative (Figure 24D) produces hexameric macrocycles [92] and its counterpart (Figure 
24E) which formed tetrameric species [93]. 
 
Figure 24. Adenine derivatives used to form different sized macrocycles 
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Studies by Severin and co-workers came to the same conclusion that rather small 
changes in the structure of the bridging ligand determine the size of the macrocycle. They 
also pointed out that too much flexibility in the ligand might lead to the entropically 
favored dimeric species [94]. These type of macrocycles has found applications as host 
guest systems to selectively bind lithium [95-96] or fluoride ions [97].  
 
Even though metalla-supramolecular structures are very versatile and have been 
used to generate confined environments able to encapsulate compounds [98-100], protect 
and stabilize an otherwise unstable molecule [101-105], inhibit telomerase by stabilizing 
G-quadruplexes [106], recognize and trap specific guest molecules [107-109], or even act 
as microreactors for specific reactions [110-113], they are rarely evaluated for their 
biological activity. A series of trinuclear arene ruthenium compounds bridged by 
aminomethyl-substituted 3-hydroxy-2-pyridone ligands were recently evaluated in vitro 
which fragmented and gave rise to mononuclear active species [114]. Hannon and co-
workers has synthesized self-assembled dinuclear ruthenium compounds with helical 
shape. These chiral compounds were found to bind in the major groove of DNA inducing 
intra molecular coiling [115] . 
 
We decided to produce a series of rectangular arene ruthenium rectangles and 
evaluate their biological activity. Previous research by Süss-Fink and co-workers proved 
that rectangles from arene ruthenium compounds are obtainable by using a tetradentate 
oxalato bridging ligand connecting two metal centers and combining this with a bidentate 
bridging ligand. In the same manner larger rectangles can be produced by changing the 
size of the tetradentate ligand and by using the “molecular clip” approach to avoid 
formation of trinuclear species. This chapter will describe the synthesis, characterization, 
electrochemistry and biological activity of rectangles synthesized with quinonato bridged 
molecular clips. Even though some of these rectangles were produced in parallel by Jin et 
al. their biological activity was never before evaluated [116]. 
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4.2 Synthesis and characterization of molecular clips 
 
The chloro-bridged arene ruthenium dimer reacts with the bis-bidentate ligand 
(dihydroxo benzoquinone and chloranilic acid) at room temperature in methanol over 2 
hours to form the bimetallic species [(η6-arene)2Ru2(OO∩OO)Cl2] (arene = 
hexamethylbenzene, p-cymene; OO∩OO = 2,5-dihydroxy-1,4-benzoquinonato (dhbq), 
2,5-dichloro-3,6-dihydroxo-1,4-benzoquinonato (dchq)) 7-10 (Scheme 6). The dark 
brown purple solids are collected by filtration in high yields. They are soluble in 
chlorinated solvents and sparingly soluble in most other organic solvents like methanol 
and acetone.  
 
Scheme 6. Synthesis of bimetallic “molecular clip” of the type [(η6-
arene)2Ru2(OO∩OO)Cl2] (7-10) 
 
In the 1H NMR spectra the signals from the p-cymene moiety is in general shifted 
slightly downfield in comparison to the chloro dimer by about 0.3 ppm. The arene signals 
are also separated by an additional 0.1 ppm due to the deshielding effect of the quinonato 
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ligand. The signal of the dhbq protons in compounds 7 and 9 are also shifted upfield in 
comparison with free dhbq-H2 by 0.3 ppm. 
 
 
4.3 Synthesis and characterization of supramolecular rectangles 
 
4.3.1 Pyrazine bridged rectangles 
 
The dinuclear arene ruthenium complexes [(η6-arene)2Ru2(OO∩OO)Cl2] (7-10) 
react in methanol at room temperature with silver triflate to remove the chloride ligands. 
The activated methanolate species produced in situ can adopt a syn symmetry. It then 
reacts with the N∩N donor ligand pyrazine to give the metalla-cyclic tetranuclear cations 
11-14. The rectangles are obtained as their triflate salts (Scheme 7).  
Ru
R
Ru
R
O O
OO
Cl
Cl
XX
1. Ag(O3SCF3)
N N2.
Ru
R
Ru
R
O O
OO
XX
Ru
R
Ru
R
OO
O O
X X
N N
N N
R
=X = H11
12
13
14
X = Cl
X = H
X = Cl R
4+
=
 
Scheme 7. Synthesis of pyrazine rectangles, compounds 11-14 
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The tetranuclear compounds [11-14][O3SCF3]4 dissolve only sparingly in acetone 
and dichloromethane and show rapid decomposition in dimethylsulfoxide. The 1H NMR 
spectra of 11-14 display a singlet due to the pyrazine protons. Unlike free pyrazine, 
where the proton signal is found at 8.61 ppm in acetone-d6, the signal in 11-14 appears 
slightly shifted downfield at 8.7 ppm. Upon formation of the cationic tetranuclear 
metalla-rectangles, the methyl and isopropyl signals of the p-cymene ligands in 11 and 12 
remain almost unchanged as compared to complexes 7 and 8, while the aromatic protons 
of the p-cymene ligands are shifted downfield. On the other hand, the proton signal of the 
dhbq bridging ligands in 11 and 13 is shifted upfield as compared to the parent 
complexes 7 and 9. The infrared spectra of 11-14 are dominated by absorptions of the 
coordinated N∩N and OO∩OO ligands, which are only slightly shifted as compared to 
the free ligands. In addition to the N∩N and OO∩OO signals, strong absorptions due to 
the triflate anions (1260(s), 1030(s), 638(m) cm-1) are also observed in the infrared 
spectra of the salts. 
 
 
4.3.2 4,4’-Bipyridine bridged rectangles 
 
The synthesis of these rectangles follows the same procedure as the previous 
ones. The bimetallic clip reacts in methanol at room temperature in the presence of silver 
triflate which removes the chloride, and the methanolated clip is then mixed with the 
bridging N∩N donor ligand to produce the metalla-rectangles [15-18][O3SCF3]6 as their 
triflate salts in good yields as dark red solids (Scheme 8). Compounds [15-18][O3SCF3]4 
are soluble in polar organic solvents such as dichloromethane, acetone, methanol, 
dimethylsulfoxide and also in water. 
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Scheme 8. Synthesis of 4,4’-bipyridine bridged rectangles, compound 15-
18 
 
The 1H NMR spectra display two doublets originating from the 4,4’-bipyridine 
bridging ligand. The signal from the α-proton is found in acetone-d6 at 8.54 ppm for 15 
and 16 and at ~8.40 ppm for 17 and 18 shifted slightly upfield from the free ligand at 
8.72 ppm. The β-proton signal is found at ~8.04 ppm (15, 16) and ~8.10 ppm (17, 18) 
respectively which is as well downfield shifted by about 0.3 ppm from the free 4,4’-
bipyridine. Signals from the methyl and isopropyl groups of p-cymene and 
hexamethylbenzene remain virtually unchanged whereas the arene proton signals of 
p-cymene shift downfield, as well the dhbq proton in complex 15 and 17 shifts upfield. 
The IR spectra are as well dominated by the N∩N and OO∩OO ligands with the 
additional absorptions of the triflate anions. 
 
The single crystal X-ray structure analysis of [17][O3SCF3]4 confirms the 
expected rectangular structure. The molecular structure is presented in Figure 25. The 
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cation 17 contains four ruthenium metal centers bonded to a hexamethylbenzene ligand, 
which are bridged by the dianionic OO∩OO ligand through its four oxygen atoms and 
linked by the neutral N∩N ligand 4,4’-bipyridine. The Ru-N and Ru-O distances 
observed in 17 are comparable to those found in the hexacationic metalla-prisms. The 
4,4’-bipyridine linkers show a twist of 4.6° between the two pyridyl units, which is 
comparable to that found in other 4,4’-bipyridine bridged ruthenium complexes [117].  
 
 
Figure 25. Capped sticks representation of cation 17, O3SCF3 and H 
atoms omitted for clarity 
 
Interestingly, [17][O3SCF3]4 forms in the solid state one dimensional channels 
along the b axis with intramolecular Ru-Ru separations of 7.9 and 11.3 Å. A similar 
arrangement along the c axis has been found in the crystal structure of [16][O3SCF3]4, 
with almost identical Ru-Ru separations (7.9 and 11.2 Å ) [116]. In both structures the 
triflate anions are located between the rectangular channels. However, in [16][O3SCF3]4 
disordered water molecules are observed in the cationic molecular rectangle as compared 
to [17][O3SCF3]4 for which no solvent molecules are observed in the hydrophobic cavity. 
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4.3.3 1,2-Di(4-pyridyl)ethylene bridged rectangles  
 
The synthesis follows the same procedure using 1,2-di(4-pyridyl)ethylene as N∩N 
ligands thus producing the metalla-rectangles [19-22][O3SCF3]4 as their triflate salts in 
good yields as dark red solids (Scheme 9). The triflate salts are like the 4,4’-bipyridine 
bridged compounds soluble in polar organic solvents and in water. 
 
Scheme 9. Synthesis of 1,2-di(4-pyridyl)ethylene bridged rectangles, 
compound 19-22 
 
The 1H NMR spectra naturally display two doublets originating from the aromatic 
ring of the bipyridine bridging ligand but also a singlet from the ethylene protons. The 
signal of the α-proton appears as a doublet at ~8.33 ppm for the p-cymene containing 19 
and 20 and at ~8.20 ppm for the hexamethylbenzene containing 21 and 22. Compared to 
the 4,4’-bipyridine bridged complexes these shifts are 0.1 ppm larger (0.3 ppm for 19 and 
20, 0.4 ppm for 21 and 22) in comparison with the free ligand. The signal of the β-proton 
is in this case as well shifted downfield but by about 0.2 ppm for compounds 19-22, with 
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a slightly higher shift for the chloro containing complexes 20 and 22. As in the case of 
the 4,4’-bipyridine containing rectangles the signals of the aromatic protons of p-cymene 
complexes are shifted downfield whereas the methyl groups remains virtually unchanged, 
there is also an upfield shift of the dhbq protons of 19 and 21. The infrared spectra is as 
previously mentioned also in this case dominated by the N∩N and OO∩OO ligand 
absorptions and the absorptions of the triflate anions. 
 
The single-crystal X-ray structure analysis of [22][O3SCF3]4 confirms that the 
1,2-di(4-pyridyl)ethylene also forms the expected rectangular structures: The molecular 
structure being presented in Figure 26. Cation 22 contain four ruthenium metal centers 
bonded to a hexamethylbenzene ligand, which are bridged by the dianionic OO∩OO 
ligand through its four oxygen atoms and linked by the neutral N∩N ligand. The Ru-N 
and Ru-O distances observed in 22 and 17 are comparable to those found in the 
hexacationic metalla-prisms [guest⊂(η6-arene)6Ru6(4-tpt)2(2,5-dihydroxy-1,4-
benzoquinonato)3][O3SCF3]6 (guest = pyrene, benzo[e]pyrene, Pt(acetylacetonato)2, 
hexamethoxytriphenylene) [118-120].  
 
Figure 26. Capped sticks representation of cation 22, O3SCF3, H atoms 
and solvent molecules omitted for clarity 
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As expected, the molecular structure of [22][O3SCF3]4 shows a larger cavity (7.9 
× 13.6Å2 ). Upon crystallization of [22][O3SCF3]4 from a chloroform/diethyl ether 
mixture, two diethyl ether molecules are encompassed in the hydrophobic cavity of 
cation 22. A similar crystal packing has been observed in [20][O3SCF3]4 in which highly 
disordered solvent molecules were found in the rectangular 7.9 × 13.5 Å2 cavity [116]. 
 
 
4.4 Electrochemical properties 
 
Electrochemical studies were done in collaboration with Petr Štěpnička of Charles 
University (Czech Republic). Compounds 7-10 and [15-22][O3SCF3]4 have been studied 
by cyclic voltammetry at a platinum disk electrode. The measurements were performed 
on ca. 0.5 mM (or saturated) dichloromethane solutions containing 0.1M Bu4NPF6 as the 
supporting electrolyte. Pertinent data are summarized in Table 3.  
 
The redox response of the dinuclear complexes 7-10 is roughly similar, the 
compounds displaying one or two well-separated oxidations and one or two reductions in 
the accessible potential range. Unfortunately, the reduction waves are difficult to study, 
as they occur at the upper limit of the potential window provided by the solvent. Complex 
7 shows two well-separated irreversible reductions at -1.20 and -1.89 V and an oxidation 
at around +1.0 V (Figure 27).  
 
Replacement of dhbq with dchq bridges such as in 8 results in a shift of the 
reductive waves to less negative potentials while making the single oxidation more 
difficult (Table 3). In addition, the presence of the dchq ligand renders the first reduction 
wave reversible (Figure 28). The wave is observed with full electrochemical reversibility 
when recorded with the switching potential set before the second reduction process at 
scan rates down to 0.1Vs-1. However, upon extending the scan range further beyond the 
second reduction wave, the anodic peak current due to the first wave becomes lower than 
its corresponding cathodic counterpeak. 
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Table 3. Summary of electrochemical data of complexes 7-10 and 15-22 
aPotentials are given relative to ferrocene/ferrocenium. Peak potentials are 
quoted for irreversible (ir.) processes (Epa or Epc). The potentials for 
reversible (rev.) couples are defined as the mean of the anodic and 
cathodic peak potentials: E°′=1/2(Epa + Epc). bA prepeak is observed at -
1.65 V. c See text. d The most negative peak is hidden by decomposition of 
the base electrolyte and some decomposition processes. 
Compound E[V] 
7 -1.20 (ir.), -1.89 (ir.); ca. +1.0 (ir.) 
8 2 -0.90 (rev.), -1.76 (ir.),b ca. +1.1 (ir.) 
9 3 -1.37 (ir.), +0.76 (ir.), ca. +1.1 (ir.) 
10 -1.06 (rev.), ca. -2.0 (ir.), ca. +0.76 (ir.) 
15[O3SCF3]4 -0.68 (rev.),c -1.39 (ir.), -1.90 (ir.) 
16[O3SCF3]4 -0.45 (rev.),c -1.15 (rev.)c,d
17[O3SCF3]4 -0.82 (rev.)c, ca. -1.6 (ir.) 
18[O3SCF3]4 -0.55 (rev.), -1.35 (rev.)c
19[O3SCF3]4 -0.70 (rev.), -1.42 (ir.), ca. -1.9 (ir.) 
20[O3SCF3]4 -0.45 (rev.), -1.19 (rev.)c, ca. -1.9 (ir.) 
21[O3SCF3]4 -0.56 (rev.),c -1.44 (ir.) 
22[O3SCF3]4 -0.57 (rev.),c -1.41 (rev.)c, ca. -2.0 (ir.) 
 
 This points to some coupled chemical processes that consume the 
electrogenerated species and is in accordance with the fact that the second reduction is 
accompanied by adsorption processes or decomposition. The replacement of the p-
cymene ligand for hexamethylbenzene (7 → 9 and 8 →10) leaves the redox pattern 
virtually unchanged, but the respective waves appear shifted to more negative potentials. 
Apparently, the higher donor ability of the hexamethylbenzene ligand makes any electron 
addition more difficult while facilitating the oxidative processes. For 9, this “shift” allows 
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for observation of two oxidative waves at +0.76 and ca. +1.1 V, whereas the expected 
second reduction falls outside the accessible potential range. 
 
E[V]
i [
μA
] 
 
Figure 27. Cyclic voltammograms of 7 (0.5 mM in CH2Cl2 at Pt-disk, 
scan rate 0.1Vs-1 ) 
 
E[V]
i [
μA
] 
 
Figure 28. Cyclic voltammograms of 8 (0.5 mM in CH2Cl2 at Pt-disk, 
scan rate 0.1Vs-1 ) 
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In analogy to the previous reports dealing with electrochemistry of diruthenium 
complexes featuring dhbq and dchq bridges [121-123], we can formally assign the 
cathodic processes to one-electron reductions that occur predominantly at the bridging 
ligand and attribute the oxidations to the Ru(II)/Ru(III) couples. Nevertheless, this 
assignment is only qualitative, particularly if one considers the extensive mixing of the 
metal-based orbitals with those located at the bridging ligands as established by 
theoretical calculations [122]. 
 
Like in the case of the dinuclear compounds, the overall redox response of the 
tetraruthenium complexes 15-22 is analogous. Compared with their diruthenium 
precursors, complexes 15-22 bear a high positive charge and, hence, are more prone to 
reduction, whereas their oxidative waves are either observed at the onset of the base 
electrolyte decomposition (19) or not observed at all due to their highly positive redox 
potentials. The p-cymene ruthenium complex possessing 4,4’-bipyridine bridges, 
compound 15, undergoes first a reversible reduction at -0.68 V followed by two 
successive irreversible reductions at -1.39 and -1.90 V (Figure 29). The following redox 
steps apparently influence the first one: When the scanning is performed just over the 
first reduction, the first reduction is observed with full electrochemical reversibility. 
Upon increasing the switching potential so that the scan involves the subsequent redox 
step(s), the oxidative peak due to the first wave is observed with a significantly lower 
peak current. This again points to some associated follow-up associated processes that 
consume the electrogenerated product(s). 
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Figure 29. Cyclic voltammograms of 15 (0.5 mM in CH2Cl2 at Pt-disk, 
scan rate 0.1V; first scan ⎯ , second scan ----) 
 
i [
μA
] 
E[V  
Figure 30. Cyclic voltammogram of 20 (0.5 mM in CH2Cl2 at Pt-disk, 
scan rate 0.1V; first scan ⎯ , second scan ----) 
 
The behavior of the analogous compound 19 featuring 1,2-bis(4-pyridyl)ethylene 
linkers is practically identical, except that all the waves are shifted to slightly more 
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negative potentials. By contrast, the change of the bridge for the dchq anion has a more 
pronounced effect. The first two waves in 20 (Figure 30) and 16 are observed shifted to 
more positive potentials, which is in accordance with the electron-withdrawing nature of 
the chloride substituents replacing two hydrogen atoms at the OO∩OO bridging ligand. 
In addition, both waves bear clear signs of electrochemical reversibility, the first wave 
being observed with full reversibility when the switching potential is set just after the first 
reduction. The following wave can be described as quasi-reversible, showing a lower 
peak current for the back scan peak (anodic) than for the forward (cathodic) peak 
(ipc>ipa). Moreover, scanning further beyond the second wave (i.e., toward more negative 
potentials) markedly lowers the reversibility of the first redox step, causing an increase in 
the separation of the counterpeaks and lowering of the current of the respective anodic 
counterwave. The redox behavior of 17-21 and 18-22 is complicated by adsorption 
phenomena that become particularly pronounced upon repeated scanning and reduce the 
reversibility and reproducibility of the cyclic voltammograms. This is particularly the 
case of 21, which shows additional ill-defined reductive peaks and a strong stripping peak 
in the anodic region. 
 
 
4.5 Biological activity 
 
The biological activity was tested in collaboration with Prof. Paul Dyson and co-
workers at the EPFL (Switzerland). The anti-proliferative activity of the water soluble 
compounds containing the ligands 4,4’-bipyridine (15-18) and 1,2-bis(4-pyridyl)ethylene 
(19-22) was evaluated against the A2780 ovarian cancer cell line. All complexes exhibit 
moderate to excellent activity with IC50 values in the range 4-66 μM (Table 4). In each 
case, the hexamethylbenzene complexes exhibit lower IC50 values than their p-cymene 
analogues, probably resulting from increased uptake due to their greater lipophilicity. 
Similarly, complexes containing the dhbq linkers are generally more active than the less 
lipophilic dchq analogues.  
 
  53  
Supramolecular Rectangles   
Table 4. IC50 values of complexes 15-22 on A2780 human ovarian cancer 
cells after 72h exposure 
 
Compound IC50 (μM) 
15[O3SCF3]4 66 
16[O3SCF3]4 43 
17[O3SCF3]4 27 
18[O3SCF3]4 33 
19[O3SCF3]4 6 
20[O3SCF3]4 29 
21[O3SCF3]4 4 
22[O3SCF3]4 23 
cisplatin 2 
 
 
 
 
 
 
 
 
 
 
 
There does not appear to be a correlation between the redox potentials of the 
compounds and their cytotoxicity, which is perhaps not surprising since it is generally 
considered that Ru(III) compounds are reduced to Ru(II) compounds inside the reductive 
environment of a tumor (with Ru(0) not biologically accessible), and therefore the 
compounds investigated herein are already in the active oxidation state. 
 
Interestingly, the large rectangles incorporating 1,2-bis-(4-pyridyl)ethylene and 
dhbq linkers (complexes 19 and 21) are up to an order of magnitude more cytotoxic (IC50 
≤ 6 μM) than the 4,4’-bipyridine containing cations (IC50 ≥ 30 μM). The reason for this 
effect is not clear but it could be linked to the increased flexibility of the 1,2-bis(4-
pyridyl)ethylene linker that may allow the rectangular structures to adapt their shape to 
better fit with a molecular target. However, it cannot be ruled out that the tetranuclear 
cations fragment once inside a cell and that the fragments induce the cytotoxic effect, it is 
even quite likely that fragmentation occurs based on a study of chemically similar 
compounds [124]. Another study of similar metalla-rectangles by Navarro and Barea 
treated interactions with DNA and showed that these types of complexes induce changes 
in the shape of DNA strands. They also proposed possible binding in the major groove of 
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DNA which might be responsible for the shape changing properties, however if these 
complexes are able to enter the nucleus has yet to be proven alas another mechanism 
might be responsible for their activity. The chlorinated clip was found inactive whereas 
the triflate activated species exhibited some activity. These rectangles were as well found 
active against the A2780 cell line but much less against a lung cancer cell line which 
suggests low general toxicity [125].  
 
 
4.6 Conclusions 
 
With the goal to produce supramolecular assemblies with biological activity we 
have produced a series of supramolecular rectangles in good yields soluble in most polar 
organic solvents and water. Some of these complexes have shown high biological activity 
even though the mechanism of their activity is still unknown, whereas some were not 
sufficiently stable for such studies. Tests on similar compounds suggest low general 
toxicity. The positive biological results prove the possibility to use these systems for 
biological applications although selectivity has yet to be proven. 
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5. Supramolecular Prismatic Carceplexes 
 
5.1 Introduction 
 
Three dimensional assemblies are obtained following the same strategy as for the 
two dimensional systems by mixing angular units with linear or planar ones. However in 
this case one of the two components needs to have three connecting points. Fujita and co-
workers were the first to synthesize this type of system using the same [Pd(en)]2+ corners 
but connected with the tritopic ligand 2,4,6-tris(4-pyridyl)-1,3,5-triazine (tpt) to produce 
a three dimensional cage structure (Figure 31) [126]. 
 
Figure 31. Three dimensional Pd cage [Pd6(en)6(tpt)4]12+ synthesized by 
Fujita [126] 
 
They investigated the host guest chemistry of this octahedron which is able to 
encapsulate adamantane, the hydrophobic cavity can also be used to carry out reactions 
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for example Diels Alder catalytic reactions for which acceleration by a factor of 100 was 
observed [127].  
 
Stang and co-workers followed shortly after and successfully synthesized a chiral 
octahedron based on the slightly larger tritopic ligand 1,3,5-tris[(4-pyridyl)- 
ethynyl]benzene and chiral corners in the form of [(R-(+)-BINAP)M(O3SCF3)2] (M = Pt, 
Pd, and BINAP = 2,2’-bis(diphenylphosphino)-1,1’-binaphthyl). This complex was as 
expected found to be optically active [128].  
 
So even for three dimensional structures given specific angles of the units a 
variety of structures could theoretically be obtained through rational design. A mixture of 
tridentate planar and linear ligands with 90° corners would produce a triangular prism 
(Figure 32A), planar tridentate ligands with 78-84° angle units would give the fore 
mentioned octahedron (Figure 32B), tridentate 90° angular units in combination with 
linear units would form a cube (Figure 32C), planar tridentate ligands with an angular 
unit of 109.5° bonding angle would take the shape of a cuboctahedron (Figure 32D) 
whereas tridentate tetrahedral units 109° combined with linear units would take the shape 
of a dodecahedron (Figure 32E) . 
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Figure 32. Three dimensional shapes by supramolecular building blocks 
through rational design [74] 
 
Although the angles are important they will not alone determine the final 
structure, as mentioned before where components that geometrically should form squares, 
very often triangles will be obtained instead. The formation of larger structures is 
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determined by the angle but also the type of the building block, if the building block is 
flexible these degrees of freedom are frozen upon complexation, an energy loss which is 
acceptable for small structures but not in larger ones. The key to producing large 
structures is rigid building blocks with few degrees of freedom. Concentration of the 
building blocks and solvent choice are two other important factors as they affect the 
entropy of formation for the complex [129].  
 
Cubic structure is large and demands many components, 8 corner units and 12 
linear units. By rational design using the fairly rigid 4,4’-bipyridine ligand with 
Ru([9]aneS3) corners, which does not sterically affect the bond angles of the ligands, 
Thomas and co-workers managed to assemble a molecular cube (Figure 33) [130]. 
 
Figure 33. Synthesis of a molecular cube [130] 
 
Three dimensional supramolecular structures can also be obtained from other 
types of systems than two building block assemblies. Lehn and co-workers produced a 
cylindrical assembly in 1993, before Fujita’s octahedron, from three different types of 
building blocks, three linear tetradentate, two planar hexadentate ligands and six Cu+ ions 
(Figure 34). If building blocks are mixed in the correct stoichiometry (3:2:6) the cylinder 
is the only product obtained [131]. 
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Figure 34. Cylindrical assembly from three different building blocks [131]  
 
Another system that involves three different building blocks is a prismatic 
assembly by Fujita and co-workers. It is built up by two tpt panels, six Pd corners and 
three pyrazine bridging ligands (Figure 35). However this prism needs a template to form 
quantitatively. A template is a molecule that the building blocks can organize themselves 
around but does not bind to. In the synthesis of the prism in Figure 35 
hexamethoxytriphenylene was used, after the prism formed the template could be 
removed and the cage still remaining stable (Figure 35) [132].  
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Figure 35. Templated synthesis of a molecular prism [132] 
 
Templates not only help formation of certain assemblies but can also determine 
the final shape. An example of this is another structure by Fujita and co-workers where 
they examined the assembly of the tetradentate ligand 3,5-bis(3-pyridyl)-1-(3,5-
pyrimidyl)-benzene and Pd corners. The presence of a large guest like dibenzoyl induced 
an open square pyramidal cone whereas a small guest like CBr4 templated a closed 
tetrahedron structure (Figure 36) [133-134]. 
62 
  Supramolecular Prismatic Carceplexes   
 
Figure 36. Structures of self-assembly based on template [133-134] 
 
Supramolecular prisms can be obtained without using templates, this was 
investigated by Stang and co-workers. They managed to synthesize several prisms from 
the “molecular clip” strategy using both planar [135] and tetrahedral [136] tritopic units 
(Figure 37).  
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Figure 37. Molecular clip synthesis of a supramolecular prism 
 
Using this strategy we rendered several prismatic structures based on arene 
ruthenium building blocks. Earlier results have proved that using arene ruthenium 
bimetallic complexes as molecular clips produces supramolecular rectangles. Having two 
90° angular coordination sites the arene ruthenium complexes used as a bimetallic 
molecular clip could also produce prisms if mixed with tritopic ligands. The first arene 
ruthenium prisms to be synthesized were the chloro- and oxalato-bridged prisms. The 
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oxalato-bridged prism is synthesized by the metallic clip strategy (Figure 39), whereas 
for the chloro-bridged prism there are two possible methods. Either the chloro-bridged 
arene ruthenium dimer can be reacted with the tritopic panel ligand in water in the 
presence of silver triflate or the dimer directly reacted with the tritopic ligand which 
breaks the chloro-bridge forming a trinuclear ruthenium panel, 1 equivalent of silver 
triflate per ruthenium is then added to remove half of the chlorides which allows for the 
chloro-bridge to be reformed (Figure 38) [137-138]. 
 
  
Figure 38. Two possible methods to obtain the chloro-bridged prism [137-
138] 
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Figure 39. Molecular clip synthesis of oxalato bridged prism [137-138] 
 
Although interesting 3D structures the distance between the two panels was too 
small to incorporate a guest molecule, a new larger molecular clip was therefore 
employed. Using dihydroxyquinone as bridging ligands to increase the Ru-Ru distance 
from 5.5 Å in the oxalato complex to 7.9 Å (Figure 40), introduction of guest molecules 
was possible.  
 
Figure 40. Molecular clips and their Ru–Ru distances 
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When using large aromatic molecules like hexamethoxytriphenylene as a template 
for the synthesis of the prism, it was realized that the guest cannot be removed 
afterwards. Instead a carceplex is produced i.e. the guest is trapped and cannot escape 
until breaking of the prism (Figure 41) [139]. The prisms are water soluble whereas the 
cavity is hydrophobic, they also contain arene ruthenium moieties which are biologically 
active. With this in mind the highly insoluble metal complexes Pd(acac)2 and Pt(acac)2 
were encapsulated inside the prism solubilizing them (Figure 42). They were tested for 
biological activity and while the cage itself is active, the activity is increased in a 
synergistic fashion for the metal complex containing carceplex, especially the Pd 
complex. The M(acac)2 complexes are not water soluble which is why their activity is 
difficult to test, but inside the prism they are hidden and like a Trojan horse the prism 
transport these complexes into the cell where they can be released [119]. 
 
Figure 41. Synthesis of prismatic carceplexes [139] 
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Figure 42. Synthesis of carceplex, M(acac)2 incorporated into prism [119] 
 
 
5.2 Supramolecular prisms with aromatic guests 
With earlier studies in mind we wanted to further investigate the carceplex 
properties of this type of prism with different sized planar aromatic guests. The biological 
activity is also a very interesting subject and by testing aromatic systems varying their 
substituents, we can compare the effect on the activity, this work is presented in this 
chapter. 
 
 
5.2.1 Synthesis 
 
These types of prisms are synthesized by an analogous method to the rectangles. 
The bimetallic clips 7-10 are first reacted with silver triflate to produce the methanolate 
species, this then reacts with the tritopic panel tpt in methanol at room temperature 
overnight (Scheme 10). The prisms 23-26 are isolated in good yields as their triflate salts. 
They are soluble in most polar organic solvents and water. 
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Scheme 10. Synthesis of supramolecular prisms 23-26 
 
Synthesis of the respective carceplexes follows the same procedure except that the 
bimetallic clip is added to tpt in methanol in the presence of the aromatic guest (pyrene, 
fluoranthene, benzo[e]pyrene, triphenylene and coronene) (Scheme 11), this reaction 
does not affect the yield or the solubility of the prism, moreover no traces of empty prism 
were observed. 
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Scheme 11. Synthesis of carceplexes [guest⊂23-26]6+
 
 
5.2.2 Studies by NMR spectroscopy 
The preference of cage 23 for different aromatic molecules has also been studied. 
If a 1:1:1 mixture of coronene, triphenylene and pyrene is initially added, before the 
formation of cage 23, only coronene is found encapsulated by the cage, 
[coronene⊂23][O3SCF3]6 being exclusively isolated after workup. Similarly, just 
triphenylene is encapsulated if a 1:1 mixture of triphenylene and pyrene is used. 
Therefore, it is clear that cage 23 prefers aromatic molecules in the order coronene > 
triphenylene > pyrene. The formation of these inclusion systems can easily be monitored 
by 1H NMR spectroscopy. As expected, the 1H NMR spectrum of 23 shows a well 
organized structure with a quite simple set of signals. However, unlike the empty cage 
23, where the Hα and Hβ of the pyridyl groups are found at expected positions (8.77 and 
8.71 ppm in acetone-d6) as compared to the uncoordinated tpt unit, upon encapsulation of 
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an aromatic molecule, the Hα and Hβ signals are strongly shifted upfield (see Figure 43). 
Moreover, the protons (Hq) of the dhbq bridging ligands are shifted downfield, while the 
signals of the aromatic protons (Har) of the p-cymene ligand remain almost unchanged 
upon insertion of an aromatic molecule. Similarly, the protons of the methyl and 
isopropyl groups of the p-cymene ligand are not chemically affected by the presence of 
the large aromatic guest within the cavity of 23. 
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Figure 43. Aromatic region of 1H NMR spectrum of 23, pyrene⊂23, 
triphenylene⊂23, benzo[e]pyrene⊂23 and coronene⊂23 
 
For comparison, triphenylene as well as fluoranthene were encapsulated in the 
different cages 23-26. The carceplex properties of the four cages are all the same, and the 
encapsulation of triphenylene by 23-26 is clearly demonstrated by 1H NMR spectroscopy 
(see Figure 44). The two signals associated with the protons of the encapsulated 
triphenylene molecule (Hg and Hg’) are well separated and shifted upfield due to the 
special environment provided by the hydrophobic cavity of the cages. Indeed, Hg is 
shifted by 1.2 ppm, while Hg’ is shifted by as much as 3.6 ppm, suggesting a strong 
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interaction between triphenylene and the components of the cage, especially the tpt units. 
Similarly, the protons (Hg) of encapsulated fluoranthene molecules in cages 23-26 are 
strongly shifted upfield as compared to free fluoranthene (see Figure 45). 
 
 
⊂ 26 
⊂ 25 
⊂ 24 
⊂ 23 
 
Figure 44. Aromatic region of the 1H NMR spectrum of triphenylene⊂23-
26 and free triphenylene 
 
Interestingly, in the pyrene⊂23, fluoranthene⊂23, and benzo[e]pyrene⊂23 
systems, in which the cage symmetry (D3h) does not match the encapsulated molecule 
symmetry (D2h), only the minimal numbers of signals are observed for 23, even at low 
temperature (-50 °C). This suggests that in solution an unrestricted rotation of the large 
aromatic molecule within the hydrophobic cavity of 23 takes place. One-dimensional 
ROESY 1H NMR experiments confirm the spatial proximity of the different components 
of the empty cages 23-26. Indeed, in 23, a strong interaction between the proton (Hq) of 
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the dihydroxybenzoquinone and the Hα of the tpt units is observed. Moreover, but only 
for the filled cage triphenylene⊂23, intense cross-peaks are observed between the protons 
of the encapsulated molecule (Hg and Hg’) and the protons of the different connecting 
components of the cage molecule (Hq, Hα, and Hβ) (see Figure 46).  
 
⊂ 26 
⊂ 25 
⊂ 24 
⊂ 23 
 
 
Figure 45. Aromatic region of the 1H NMR spectrum of fluoranthene⊂23-
26 and free fluoranthene 
 
This strong interaction between the encapsulated molecule and the cationic cage 
23 suggests an eclipsed conformation of the tpt-triphenylene-tpt π-stacking arrangement. 
This is in agreement with the conformation observed in [C18H6(OMe)6⊂23]6+ [139] and in 
the prismatic cage [Pt6(NH2CH2CH2NH2)6(tpt)2(C4H4N2)3]12+ encapsulating also a 
hexamethoxytriphenylene molecule [132]. However, the other systems show no cross-
  73  
Supramolecular Prismatic Carceplexes    
peaks between the protons of the aromatic molecule and the protons of the components of 
23, as expected for rotationally unrestricted encapsulated molecules. 
 
 
Figure 46. 1-D ROESY spectrum (400 MHz, acetone-d6) and schematic 
representation of the corresponding cross-peaks observed in the system 
triphenylene⊂23 
 
 
5.2.3 Analysis by mass spectroscopy 
 
The stability of cage 23 is remarkable, and the encapsulation of the large aromatic 
molecule is definitive, even under mass spectrometry conditions. The ESI-MS spectra of 
triphenylene⊂23, benzo[e]pyrene⊂23, and coronene⊂23 show peaks corresponding to 
[aromatic⊂23 + (O3SCF3)4]2+ at m/z 1637.6, 1649.6, and 1673.6, respectively. These 
peaks have been assigned unambiguously on the basis of their characteristic Ru6 isotope 
pattern. Furthermore, in the ESI-MS spectra of pyrene⊂23, triphenylene⊂23, 
benzo[e]pyrene⊂23, and coronene⊂23, major peaks corresponding to [23+(O3SCF3)4]2+ 
at m/z1523.6,[{(η6-p-iPrC6H4Me)4Ru4(tpt)2(C6H2O4)2}+ (O3SCF3)2]2+ at m/z 1070.1, and 
[23 +(O3SCF3)3]3+ at m/z 966.1 are observed as well. 
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5.2.4 X-Ray crystallography 
 
Single crystals of [pyrene⊂23][O3SCF3]6 and [benzo[e]pyrene⊂23][O3SCF3]6 
suitable for X-ray structure analysis were obtained by the slow diffusion of benzene in an 
acetone solution of the salts. The two molecular structures show parallel π-stacking 
interactions between the aromatic rings of the tpt subunits and the large aromatic 
molecule (see Figures 47, 48).  
 
The single-crystal X-ray structure analyses of [pyrene⊂23][O3SCF3]6 and 
[benzo[e]pyrene⊂23][O3SCF3]6 reveal an average Ru-Ru separation of 7.93 Å for the 2,5-
dihydroxy-1,4-benzoquinonato-bridged units and an average Ru-Ru separation of 13.2 Å 
in the plane of the tpt units: The volume of these hexanuclear metalla-prisms being on the 
order of 700 Å3. It is clear from the van der Waals representations of the carceplex 
systems pyrene⊂23 and benzo[e]pyrene⊂23 that the pyrene and benzo[e]pyrene are 
permanently encapsulated in 23 (Figure 49).  
 
The interplanar separation observed between the aromatic moieties (~3.42 Å) is 
shorter than the theoretical value calculated for this stacking mode [140], but comparable 
to the 3.46 Å separation observed between the triazine rings of two independent tpt units 
in the crystal packing of [Ir3(C5Me5)3(tpt){S2C2(B10H10)}3] [141]. The pyrene and 
benzo[e]pyrene molecules are slightly disordered within the cavity of 23, thus supporting 
the observation that these aromatic molecules are rotationally unrestricted in solution. In 
the crystal packing of [pyrene⊂23][O3SCF3]6 and [benzo[e]pyrene⊂23][O3SCF3]6, no π-
stacking interacting systems are observed between independent molecules.  
 
The empty spaces left between the cationic hexanuclear cations are filled with 
O3SCF3 anions. In order to examine the stability of cage 23 in solution, we recorded the 
1H NMR spectra in various deuterated solvents (D2O, CD2Cl2, CD3CN, (CD3)2CO, 
(CD3)2SO) with different coordinating ability. At room temperature and even elevated 
temperature, 1H NMR experiments for 23 in D2O, CD2Cl2, CD3CN, and (CD3)2CO 
showed no signal changes, indicating the destruction of the cage or the presence of free 
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tpt units. However, in deuterated DMSO, cage 23 shows additional signals attributed to 
species generated by coordination of (CD3)2SO ligands in line with decomplexation of 
the different building blocks. 
 
Figure 47. Mixed representation of pyrene⊂23 (pyrene as space-filling 
model). Hydrogen atoms and O3SCF3 anions omitted for clarity 
 
Figure 48. Mixed representation of benzo[e]pyrene⊂23 (benzoepyrene as 
space-filling model). Hydrogen atoms and O3SCF3 anions omitted for 
clarity 
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Figure 49. Top and side view representations of pyrene⊂23 (top) and 
benzo[e]pyrene⊂23 (bottom). Anions and hydrogen atoms of the aromatic 
molecules are omitted for clarity 
 
 
5.3 Encapsulation of functionalized pyrenes 
 
To investigate the effect on the prism and also to potentially increase the 
biological activity of these systems a number of functionalized pyrenes has been 
encapsulated. They possess one or two arms hanging out of the carceplex. The dangling 
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arm has an active group at the end on which reactions may be performed. Some of these 
pyrenes are commercially available and some have been synthesized. 
 
Pyrenes are known to be biologically active and especially as DNA intercalators. 
They are as well fluorescent which helps binding studies in cells. A recent study showed 
that adding a charge and DNA binding substituent on a pyrene renders them biologically 
active, as well a compound with 2+ charges was more selective towards certain cancer 
cell lines than compounds of only 1+ [142]. Incorporating pyrenes into prismatic cages 
can therefore be used to deliver these hydrophobic DNA intercalating compounds into 
cells. 
 
The pyrene derivatives were only encapsulated in prism 23 due to its solubility, 
easy accessibility as starting material and for easy monitoring of encapsulation. 
 
 
5.3.1 Synthesis of pyrenes with bioactive functional groups 
 
Two functionalized pyrenes were obtained from the reaction of 1-
pyrenemethylamine and the corresponding acid chloride of ethacrynic acid and aspirin, 
respectively, which in turn are prepared in situ from oxalyl chloride according to a 
literature method (Scheme 12) [143]. 
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Scheme 12. Synthesis of functionalized pyrene derivatives with aspirin 
(top) and ethacrynic acid (bottom) 
 
Moreover, a series of commercially available functionalized pyrenyl compounds, 
i.e. a = 1-pyrenebutyric acid, b = 1-pyrenebutanol, c = 1-pyrenemethylamine, d = 1-
pyrenemethylbutanoate, e = 1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene, f = N-
hexadecylpyrene-1-sulfonamide) and the two previously prepared (g = pyrenyl ethacrynic 
amide, h = 2-(pyren-1-ylmethylcarbamoyl) phenyl acetate), were encapsulated in the 
metalla-prism 23. 
 
The synthesis of the prismatic carceplexes with a dangling arm follows the same 
procedure as for the encapsulation of aromatic guests. Molecular clip 7 is first reacted 
with silver triflate in methanol which is then added to a mixture of tpt and the guest (a-h) 
in methanol (Scheme 13). The carceplexes [a-h⊂23][O3SCF3]6 are obtained as red solids 
in good yields and are soluble in most polar organic solvents and water. 
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Scheme 13. Synthesis of dangling arm carceplexes 
 
A two armed pyrene, 1,8-bis(3-methyl-butyn-1-yl-3-ol)pyrene, was synthesized 
from a two step synthesis starting with an iodization of pyrene followed by a Sonogashira 
coupling reaction (Scheme 14). The two isomers were separated after coupling by 
chromatography [144], thus affording the major product, 1,8-bis(3-methyl-butyn-1-yl-3-
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ol)pyrene, in good yield. This bi-functionalized pyrene derivative was encapsulated 
following the same procedure (Scheme 15). 
 
Scheme 14. Synthesis of two armed pyrene (i) 
 
Scheme 15. Synthesis of carceplex with two armed guest i⊂23 
  81  
Supramolecular Prismatic Carceplexes    
5.3.2 Characterization by NMR spectroscopy 
 
Encapsulation of pyrene-R (a-h) in 23 can be confirmed by 1H NMR 
spectroscopy. In acetone-d6 a doublet corresponding to the Hβ protons of the tpt panels 
appear at 8.71 ppm in the empty cage 23, this signal both broadens and shifts upfield by 
ca. 0.6 ppm upon encapsulation of the functionalized pyrenyl derivative. As the pyrene is 
no longer symmetric and free rotation is blocked by the dangling arm, the pyrenyl moiety 
gives rise to nine individual signals, all shifted upfield, which is as expected since the 
pyrenyl derivative is sandwiched between two tpt panels and involved in a π-stacking 
arrangement (Figure 50). 
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Figure 50. Aromatic region of 1H NMR spectrum in acetone-d6 of 23, 
pyrene⊂23 and b⊂23 
 
In contrast, the signals of the dhbq protons are shifted downfield in all systems 
and by as much as 0.4 ppm in the case of a⊂23. In general, the signals of the adjacent 
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methylene group of the pyrenyl side-chain are shifted downfield, whereas the rest of the 
signals associated to the side-chain remain virtually unchanged. 
 
To further confirm the encapsulation of the functionalized pyrenyl derivatives in 
the cavity of 23, a series of diffusion-ordered (DOSY) NMR spectra were recorded. 
DOSY is a powerful tool for studying host-guest associations in solution [145-149]. The 
diffusion coefficient depends on the shape and size of the molecules. Therefore, in a 
carceplex system in which the guest is perfectly trapped in the cavity of the host, without 
significantly affecting the size and shape of the host, the diffusion coefficient of the 
guest⊂host adduct should be almost identical to the diffusion coefficient of the host 
alone. DOSY measurements of pyrenyl derivative g, the empty cage 23, and the inclusion 
system [g⊂23][O3SCF3]6, are presented in Figure 51.  
g 
[23]6+ 
[g⊂23]6+ 
 
Figure 51. DOSY NMR spectra of g, 23 and g⊂23 in acetone-d6
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These experiments show that in g⊂23, both components possess the same 
diffusion coefficient, which is almost identical to the diffusion coefficient of the empty 
cage 23, thus confirming the encapsulation of g in 23. 
 
For the carceplex i⊂23 the structure is confirmed by 1H NMR in which the 
characteristic broadening and shift of the H protons of the tpt panels is observed. For 
i⊂23, however, two independent signals are now observed for the dhbq protons, which is 
in accordance with the symmetry and the deshielding effect produced by the proximity of 
the alkynyl bonds on four dhbq protons (6.38 ppm), with the other two dhbq protons 
appearing at 6.21 ppm. 
 
 
5.3.3 Characterization by mass spectroscopy 
 
The carceplex systems are remarkably stable and can be characterized by ESI-MS 
with loss of only 2, 3 or 4 counter ions. The characterization by ESI-MS was done in 
collaboration with Yoshihisa Sei and Kentaro Yamaguchi at Tokushima Bunri University 
(Japan). ESI-MS of all the carceplex systems corroborates their proposed structures, see 
Figure 52 for selected examples. The ESI mass spectra of [a-g⊂23][O3SCF3]6 and i⊂23 
show peaks corresponding to the cationic carceplex system with loss of 2, 3 or 4 triflate 
counter ions. In the case of h⊂23 the acetyl group of the aspirin moiety is cleaved. These 
peaks were assigned unambiguously on the basis of their characteristic isotope patterns.  
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[a⊂23 + (O3SCF3)3]3+ [b⊂23 + (O3SCF3)3]3+ [e⊂23 + (O3SCF3)3]3+  
[g⊂23 + (O3SCF3)3]3+[f⊂23 + (O3SCF3)3]3+  [h⊂23 – CH3CO+ (O3SCF3)3]3+
 
 
Figure 52. ESI-MS spectrum of selected carceplexes 
 
 
5.4 Biological activity 
 
5.4.1 Evaluation of cytotoxicity 
 
The biological activity was tested in collaboration with Prof. Paul Dyson and co-
workers at the EPFL (Switzerland). The anti-proliferative activity of 23 and all the 
inclusion systems [a-i⊂23][O3SCF3]6 was evaluated against the human ovarian A2780 
cancer cell line using the MTT assay which measures mitochondrial dehydrogenase 
activity as an indication of cell viability. The IC50 values are listed in Table 5 and are 
reported together with that of cisplatin for comparison purposes.  
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As mentioned before, there is considerable on-going interest in the anti-cancer 
properties of arene ruthenium complexes [150-153]. It should be noted that some pyrenyl 
derivatives have recently been shown to interact with various DNA and RNA 
polynucleotides and have been tentatively proposed to have potential applications in the 
treatment of certain types of tumors [142]. However, pyrene containing compounds are 
usually used as a probe in cells due to their favorable fluorescence properties [154]. Here, 
however, due to the encapsulation of the pyrene moiety into the water soluble metalla-
prism the cytotoxic effect of even very hydrophobic derivatives was assessed. 
 
Table 5. IC50 values measured on A2780 human ovarian cancer cell line 
Complex IC50 (μM) Complex IC50 (μM) 
23 23 ± 2 e⊂23 6 ± 1.5 
pyrene⊂23 9 ± 2 f⊂23 2 ± 0.6 
a⊂23 18 ± 1.5 g⊂23 3 ± 1.1 
b⊂23 21 ± 2 h⊂23 5 ± 0.4 
c⊂23 14 ± 2 i⊂23 5 ± 0.8 
d⊂23 17 ± 1 cisplatin 1.6 ± 0.6 
 
The empty cage, 23, exhibits a moderate cytotoxicity of 23 μM which is 
comparable to that of related molecular arene ruthenium and arene osmium cages 
carrying relatively high charges [119, 125, 155-156]. It should be noted that highly 
charged complexes cross cell membranes equally well as neutral complexes, and in some 
case, their ability of entering cells is superior to that of neutral compounds or compounds 
in a low charge state [157-159].  
 
Encapsulation of the pyrenyl systems into the hexaruthenium cage has either a 
negligible effect on the cytotoxicity (pyrenes a to d) or significantly increases the 
cytotoxicity (pyrenes e to i), with f⊂23 and g⊂23 being an order of magnitude more 
cytotoxic than the empty cage 23. Indeed, the cytotoxicity of f⊂23 and g⊂23 is 
comparable to cisplatin. These differences could be due to the intrinsic cytotoxicities of 
the different pyrenyl derivatives, which due to the poor water solubility of these 
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compounds could not be evaluated, or to differences in the uptake and/or further 
intracellular release of these molecules. Nevertheless, the greater activity of the inclusion 
compounds suggests a synergistic effect between the cage and its cargo. 
 
The substituent tethered to the pyrenyl ring in f⊂23, the most active compound of 
the series, contains a group that is not too dissimilar from an extensive range of 
sulfonamide-containing inhibitors of carbonic anhydrase [160]. Carbonic anhydrases are 
potential targets for anti-cancer drugs [161] and therefore it is conceivable that the high 
cytotoxicity of f⊂23 corresponds, at least in part, to the inhibition of this enzyme class.  
 
The substituent tethered to the pyrenyl ring in g⊂23, which is also a very 
cytotoxic compound, is ethacrynic acid, which is an excellent inhibitor of glutathione 
transferase and has even been investigated as a potential anti-cancer drug [162]. Indeed, 
arene ruthenium compounds with tethered ethacrynic acid moieties are also good 
glutathione transferase inhibitors and are moderately cytotoxic [163].  
 
The crystal structure of an arene ruthenium compounds containing ethacrynic acid 
embedded in the active site of the human glutathione transferase P1-1 has been reported 
[143]. Glutathione transferase catalyzes the nucleophilic attack by reduced glutathione 
(GSH) on non-polar nucleophiles, acting on a range of exogenous compounds including 
anti-cancer agents, forming part of a coordinated defense strategy to remove GSH 
conjugates from the cell [164].  
 
Consequently, inhibition of this enzyme means that an anti-cancer drug can 
function more effectively and it is possible that g⊂23 exerts its cytotoxicity by the 
ethacrynic acid derivative inhibiting glutathione transferase within the cell resulting in a 
sensitized cell that is more responsive to the empty cage, 23. Indeed, a similar increase in 
cytotoxicity, of ca. one order of magnitude, was observed for the arene ruthenium 
compound and its ethacrynic acid derivative reported previously [163]. 
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5.4.2 Uptake studies with fluoresceQFH spectroscopy 
 
The pyrene-R compound e (1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene) was 
encapsulated because it can be used as a fluorescent probe (Figure 53). Experiments 
proved that e as expected had no measurable cytotoxicity at concentrations of 20 μM due 
to low solubility but when encapsulated in the prism 23 the carceplex has a higher 
cytotoxicity than the prismatic cage on its own. 
 
Figure 53. Fluorescent pyrene-R, e 
 
Based on these results, we studied the uptake of pyrene-R (e) and pyrene-R⊂23, 
taking advantage of the natural fluorescence of pyrene-R. Interestingly, as shown in 
Figure 54 the pyrene-R inside the cage does not show fluorescence at pH 2 or pH 7, but 
at pH 12 it exhibits the typical fluorescence of pyrene-R alone.  
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Figure 54. Fluorescence spectra of e and e⊂23 at various pH, from 2 to 
12. a) Fluorescence spectrum of e at pH 12; b) fluorescence spectrum of 
e⊂23 at pH 12; c) fluorescence spectra of e⊂23 at pH 2 and 7 which do not 
show significant fluorescence 
 
The cage compound 23 does not show any fluorescence when excited at 350 nm 
(data not shown). This would suggest that once trapped inside the cage the fluorescence 
of the pyrene-R guest molecule is quenched and upon destruction of the cage complex at 
pH 12, the fluorescence due to free pyrene-R is regained.  
 
Consequently, the free pyrene-R was tracked by fluorescence microscopy 
following incubation with A2780 cells (Figure 55). An increase of fluorescence is 
observed inside the cells following treatment with pyrene-R⊂23, whereas treatment with 
pyrene-R at the same concentration only shows a modest effect. It is also noteworthy that 
for pyrene-R⊂23 accumulation in cytoplasmic organelles is observed.  
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Figure 55. Microscopy images of cells incubated with e ande⊂23 at 2 μM 
concentration 
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Recently, Puckett et al. used flow cytometry to quantify the uptake of a 
fluorescent polypyridyl ruthenium compound [165]. We exploited their technique to 
confirm the data obtained by microscopy and provide a more quantitative picture. Figure 
56 shows typical histograms obtained from the fluorescence of cells treated with 
pyrene-R and e⊂23. These data confirm the higher fluorescence of cells treated with the 
encapsulated pyrene-R in 23 and allowed the uptake of the fluorophore to be 
quantitatively assessed.  
 
Figure 56. Flow cytometry analysis of the fluorescence of the A2780 cells 
treated with e⊂23 (a) and e alone (b) 
 
Small molecules can enter cells in multiple ways, including active, that is, energy-
dependent (endocytosis or pumps), or energy-independent phenomena (passive diffusion 
or assisted diffusion) [165-167]. To provide insights into the uptake mechanism, the 
mean fluorescence, and accordingly the uptake/release of pyrene-R, as a function of 
concentration and time was monitored during incubation with e⊂23 and during chase 
(Figure 57). Figure 57 (top left) shows that the uptake of the cage does not increase 
linearly with incubation time. This observation implies that, at least in part, the cellular 
machinery is involved, for example, membrane transporters or receptors that limited the 
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rate of uptake. This inference is confirmed by the fact that the fluorescence of the cell 
does not follow linearly with the concentration of e⊂23 (Figure 57, top right).  
 
Figure 57. Influence of various treatments on the fluorescence of cells 
treated with e⊂23. The mean fluorescence of the cells was quantified by 
flow cytometry. Top left: Time course of release of e in cells treated with 
2 μM () or 4 μM () of e⊂23. Top right: Concentration dependency of 
the release of e in cells treated with e⊂23. Bottom: Monitoring of pyrene-
R fluorescence during uptake at either 37°C () or 4°C () and during 
chase after 1 hour incubation with 4 mm of e⊂23 at 37°C (S) or 4°C (×) 
 
Nevertheless, at the concentrations tested it is not possible to determine if the 
uptake reaches a plateau or increases linearly at higher concentrations. Thus we cannot 
completely exclude a passive component in the mechanism of uptake, although an 
assisted diffusion pathway fits best with the obtained data. It is worth noting that at 4°C 
92 
  Supramolecular Prismatic Carceplexes   
neither uptake nor chase of pyrene-R seems to be significantly altered compared to the 
values obtained at 37 °C (Figure 57, bottom). Hence endocytosis may be disqualified as 
uptake does not require thermal energy. 
5.5 Conclusions 
 
We have investigated a number of prismatic cages proving that with large 
aromatic compounds they form carceplexes that will not release the guest unless the cage 
is broken. This makes them very attractive for drug transportation as many anti-cancer 
drugs are cytotoxic and could benefit from selective transportation to cancer cells. As 
these systems are water soluble and keep their water solubility even after encapsulation, 
they are good candidates to transport hydrophobic drugs. Like a Trojan horse they can 
bring drugs into cancer cells before release. We have shown that a functionalized 
aromatic molecule with one or two dangling arms can be encapsulated and that there is a 
synergistic effect on biological activity between the cage and the pyrene-R encapsulated. 
We have also proven by fluorescence studies the release of the encapsulated species 
inside the cell. This motivates further investigation to encapsulate species with higher 
activity to investigate the synergic effect, possibly the active DNA binding pyrenes of 
Schmuck and co-workers [142] or tether platinum complexes to a pyrene moiety, but 
there are many highly active compounds whose water solubility is too low to be utilized 
in vivo. If these compounds target the EPR effect is still uncertain however we proved it 
is not transported into the cell by endocytosis. In vivo tests are still needed to confirm the 
selectivity of these compounds. 
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6. General Conclusions and Perspectives 
 
This thesis work deals with bio-organometallic chemistry to achieve large 
compounds with the possibility to target the EPR effect. Targeting the EPR effect is a 
recent and attractive fashion to gain selectivity for anti-cancer drugs. Moreover using 
ruthenium might reduce the general toxicity and side effect that platinum compounds 
often exhibit. A number of large arene ruthenium containing compounds has been 
synthesized and their biological activity has been evaluated.  
 
 
6.1 Dendritic systems 
 
The first part of this thesis deals with metalla-dendrimers. A number of different 
generation metalla-dendrimers were produced. Generations 1 and 2 were easily obtained 
from the commercial DAB dendrimer which is then reacted through a Schiff base 
condensation to produce the pyridyl end group dendrimer. These dendrimers can then be 
easily reacted with a ruthenium dimer to give the metalla-dendrimer in high yields. Four 
different metalla-dendrimers were synthesized and two mononuclear compounds for 
comparison. 
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.  
 
Their cytotoxicities were evaluated on A2780 human ovarian cancer cell line. The 
metalla-dendrimers exhibit moderate cytotoxicity but only as a function of the number of 
arene ruthenium complexes connected to the dendrimer. There is hence no synergistic 
effect of the dendrimer. However the results suggest that these metalla-dendrimers are 
taken up by the cells no matter the size. To test even larger systems like the 3rd and 4th 
generation would be interesting, as they might target the EPR effect more effectively. 
Introducing a charge onto these systems could also be an interesting approach as we have 
seen with the hexacationic prisms that such hexacationic systems are easily taken up by 
cancer cells, this could be done by introducing a 2,2’-bipyridyl moiety instead of the 4-
pyridyl. In addition, bidentate ligands generate in general more active ruthenium species. 
 
 
6.2 Supramolecular rectangles 
 
The second part deals with supramolecular rectangles containing arene ruthenium 
corners. These are interesting not only for their structural properties but also their 
biological potential. A straightforward and simple synthesis using the molecular clip 
strategy affords these rectangles in good yields and high purity. 
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The biological activity was evaluated on A2780 human ovarian cancer cell line. 
However the smallest pyrazine bridged rectangles were not stable enough to be tested. 
The ones tested show moderate to high cytotoxicity, judging from the differences in their 
IC50 values the activity seems to increase with lipophilicity as the hexamethylbenzene 
complexes are in general more cytotoxic and with flexibility as the 1,2-di(4-
pyridyl)ethylene complexes seem more active than the 4,4’-bipyridine derivatives.  
 
The rectangular systems activity is interesting, however more studies needs to be 
done concerning their biological mechanism. A larger series of more diverse rectangles 
needs to be done comparing activity of; more or less flexible N∩N bridging ligands; the 
impact of the charge of the complex; possibility of these complexes to bind quadruplex 
DNA. There is also a possibility that the cavity in these systems can be exploited as host 
for transportation of hydrophobic drugs. Some of these aspects are currently under 
investigation within the group. 
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6.3 Supramolecular prisms 
 
The third part deals with supramolecular prism with encapsulated aromatic 
molecules. They are easily synthesized by the same procedure as an empty prism but with 
the addition of a guest molecule. The large aromatic molecule encapsulated cannot be 
removed, thus a carceplex is formed, the only way to remove the guest is the breaking of 
the prismatic cage. Because of this property, and the fact that arene ruthenium 
compounds are biologically active, a number of functionalized pyrene species were 
encapsulated in the prismatic cage.  
 
 
 
 
Biological tests on the A2780 human ovarian cancer cell line showed that the 
activity increased for some carceplexes as compared to the empty cage 23 and free 
pyrene. The activity of the pyrenes alone cannot be tested due to their poor water 
solubility. The effect of the pyrenes with simple active groups such as acid, alcohol and 
amine is negligible as IC50 values are almost the same as for 23 alone. Some 
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functionalized species however increase the activity of the carceplex and the most active 
possesses cytotoxicity comparable to that of cisplatin.  
 
To shed some light on the mode of action of these carceplexes a fluorescence 
study of the carceplex e⊂23 was done (e = 1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene). As 
the fluorescence of the pyrene-R is quenched when encapsulated the release of pyrene-R 
from the cage could be studied. Fluorescent microscopy on cells treated with free pyrene-
R and e⊂23 revealed stronger fluorescence from cells treated with the carceplex 
suggesting that the cage aids the uptake and then releases the pyrene by breaking. Further 
tests were done to investigate the mode of uptake where an active mode of uptake was 
excluded. There is a possibility that these complexes travels across the membrane 
through passive diffusion. 
 
++ 
2 µM, 24 hours 2 µM, 24 hours 
 
 
The prismatic cages are large and could benefit from the EPR effect, although this 
has yet to be proven, there are arguments that they are not large enough for this effect. 
However we have proven that cancer cells take up these complexes but an in vivo test has 
to be done to prove selectivity.  
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Biological in vivo tests would answer some of the questions raised for these 
compounds. For instance indication of the complexes selectivity and general toxicity 
could be evaluated with in vivo tests, which in extension would guide how to orientate 
future research. 
 
Otherwise measures to increase activity can be taken. For example other types of 
compounds could be encapsulated. There are many drugs that are highly cytotoxic but 
disqualified from clinical use because of low water solubility. These prismatic cages 
could be a solution to transport such compounds into cancer cells and their high activity 
can be exploited. 
 
The encapsulation of functionalized pyrenes can also be further developed. As 
biologically active groups increased their cytotoxicity adding more active groups or using 
the DNA/RNA binding pyrenes of Schmuck et al. [142] would be interesting. For 
example tethering platinum compounds to the pyrene might be interesting, something 
which is ongoing in the laboratory. Furthermore attaching two bioactive groups to the 
two armed pyrene would be interesting for comparison with the single armed, to see the 
impact of the bioactive groups. 
 
Finally as the arene ruthenium complexes are versatile the arene may be 
derivatized. Attaching various bioactive groups to the arene could be of interest; this 
would transport one bioactive group per ruthenium into the cell increasing the activity 
sixfold as compared to an encapsulated group. However such an addition might change 
the solubility of the complex and thereby change its uptake and activity. PEG (poly 
ethylene glycol) chains could also be attached to the arene moiety making the complex 
larger and thereby increasing the possibility to target the EPR effect. 
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6.4 General conclusions 
 
We have shown that arene ruthenium complexes incorporated in large systems or 
supramolecular assemblies are of biological relevance. Almost all compounds exhibit 
moderate to high cytotoxicity when tested on the A2780 human ovarian cancer cell line. 
Tests performed by Navarro and Barea [125] suggests that at least the rectangles are not 
generally toxic, something which encourages further exploration of this field. Moreover 
we have proven activity regardless of the size of the compound, however if selectivity 
can be gained through the benefit of the EPR effect has yet to be investigated. 
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7. Experimental section 
 
7.1 General remarks 
 
7.1.1 Solvents and gases 
Solvents of analytical grade purchased from Acros organics or VWR International 
S.A.S were used for synthesis and unless otherwise stated degassed prior to use. The 
silica used for column chromatography (32-63, 60Å) was purchased from Brunshwig 
AG. The gas (N2) when utilized was supplied by Carbagas and was used directly from 
cylinder without further purification. 
 
 
7.1.2 Starting materials 
All organic starting materials were purchased from Acros organics, Sigma-
Aldrich, Fluka or TCI-Europe and used as received. The dimeric complexes [(η6-p-
iPrC6H4Me)RuCl2]2 and [(η6-C6Me6)RuCl2]2 [168], 2,4,6-tris(4-pyridyl)-1,3,5-triazine 
(tpt) [169] and diiodopyrene [144] were synthesized according to published methods. 
RuCl3 hydrate was a generous loan from Johnson-Matthey. 
 
 
7.1.3 Analytical instruments 
The 1H, 13C{1H} ROESY and DOSY NMR spectra were recorded on a Bruker 
AvanceII 400 spectrometer using the residual protonated solvent as internal standard.  
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Infrared spectra were, if not otherwise stated, recorded as KBr pellets on a Perkin-
Elmer FTIR 1720-X spectrometer.  
 
Electrospray ionization mass spectrometry conditions were recorded on a Bruker 
APEX II 9.4-tesra FT-ICR-MS equipped with an Apollo II electrospray ion source: 
sample condition 10-50 μmol/l in methanol at 30ºC, end plate voltage 3500 V, and 
capillary voltage. 
 
Elemental analyses were done by Laboratoire de chimie pharmaceutique de 
l’Université de Genève (Switzerland) or by Mikroelementar-analytisches Laboratorium 
de ETH Zürich (Switzerland). 
 
7.1.4 Electrochemistry 
 
Electrochemical measurements were carried out with a computer-controlled 
multipurpose potentiostat μAUTOLAB III (Eco Chemie) at room temperature using a 
standard Metrohm three-electrode cell with platinum disk electrode (AUTOLAB RDE; 3 
mm diameter) as the working electrode, platinum sheet auxiliary electrode, and calomel 
reference electrode (3 M KCl). The analyzed compounds were dissolved in 
dichloromethane (Fluka, absolute, declared H2O content ≤ 0.005%) to give a solution 
containing 5 × 10-4 M of the analyte and 0.1 M Bu4NPF6 (Fluka, purissimum for 
electrochemistry). In the case of poorly soluble compounds, saturated solutions were 
used. The solutions were deaerated with argon prior to the measurement and then kept 
under an argon blanket. The redox potentials are given relative to the 
ferrocene/ferrocenium reference and are reproducible within ca. ± 5 mV. 
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7.1.5 X-ray structure analysis 
 
The crystallographic analyses were done by Dr Bruno Therrien. In general the 
crystals were mounted on a Stoe Image Plate Diffraction system equipped with a φ circle 
goniometer, using Mo Kα graphite-monochromated radiation (λ=0.71073 Å) with φ 
range 0-200°, increment of 1.2° and 1.0°, respectively, 2θ range from 4.0° to 52°, Dmax -  
Dmin= 12.45 - 0.81 Å. The structures were solved by direct methods using the program 
SHELXS-97 [170]. Refinement and all further calculations were carried out using 
SHELXL-97 [170]. In all compounds the H atoms were included in calculated positions 
and treated as riding atoms using the SHELXL default parameters. All non H atoms were 
refined anisotropically, using weighted fullmatrix least-squares on F2. Crystallographic 
details can be found through each compounds CCDC number listed in appendix. 
Molecular representations were drawn with ORTEP [171] or MERCURY [172]. 
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7.2 Synthesis 
 
7.2.1 Imine pyridine dendrimers G1 and G2 
 
 
General synthesis of iminopyridyl dendrimers 
A solution of 4-pyridinecarboxaldehyde (1.23 mL, 12.9 mmol for G1, 2.46 mL, 
15.8 mmol for G2) in dry toluene (5 mL) was added dropwise to an ice-cooled solution of 
DAB-(NH2)4 (1.006 g, 3.18 mmol) in dry toluene (50 mL). The reaction mixture was 
stirred at room temperature in the presence of anhydrous MgSO4 (~10 g) for 24 h. The 
slurry was filtered and the solvent removed by rotary evaporation yielding an orange 
residue. The residue was dissolved in CH2Cl2 (20 mL), and washed with H2O (6× 20 
mL). The organic layer was collected and dried over anhydrous MgSO4. The solvent was 
then removed by rotary evaporation to yield the product as an oil, which was dried in 
vacuo.  
 
Dendritic iminopyridyl ligand G1. Yield 1.48 g (67.9%). 1H NMR (400 MHz, 
CDCl3): δ (ppm) = 8.63 (d, 8H, 3JH-H = 6.02 Hz, Har), 8.23 (s, 4H, imine), 7.52 (d, 8H, 
3JH-H = 6.04 Hz, Har), 3.63 (t, 8H, 3JH-H = 7.53 Hz, CH2), 2.52 (m, 8H, CH2), 2.38 (br t, 
4H, CH2), 1.83 (qn, 8H, CH2), 1.42 (m, 4H, CH2). 13C{1H} NMR (100 MHz, CDCl3): δ 
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(ppm) = 159.0 (CH, imine), 150.4 (CH, Arpyr), 143.0 (C, Arpyr), 159.0 (CH, imine), 150.4 
(CH, Arpyr), 143.0 (C, Arpyr), 121.8, 59.8 (CH2), 54.1, 51.7, 28.3, 25.3. IR (NaCl cells, 
CH2Cl2, cm-1): ν(imine C=N) 1648 (s), ν(aromatic C=N) 1599 (s). Anal. Calc. for C40H52N10. 
1/2CH2Cl2: C, 68.00; H, 7.47; N, 19.58. Found: C, 68.42; H, 7.50; N, 20.02%. 
 
Dendritic iminopyridyl ligand G2. Yield 1.47g (75.4%). 1H NMR (300 MHz, CDCl3): 
δ (ppm) = 8.57 (d, 16H, 3JH-H = 5.99 Hz, Har), 8.17 (s, 8H, imine), 7.48 (d, 16H, 3JH-H = 
6.03 Hz, Har), 3.56 (br t, 16H, 3JH-H = 6,49 Hz, CH2), 1.94-2.44 (overlapping m, 36H, 
CH2), 1.72 (m, 16H, CH2), 1.47 (br m, 8H, CH2), 1.39 (br m, 4H, CH2). 13C{1H} NMR 
(75 MHz, CDCl3): δ (ppm) = 159.0 (CH, imine), 150.4 (CH, Arpyr), 142.9 (C, Arpyr), 
121.8, 59.8 (CH2), 54.3, 52.3, 52.2, 51.7, 28.3, 25.2, 24.8. IR (NaCl cells, CH2Cl2, cm-1): 
ν(imine C=N) 1648 (s), ν(aromatic C=N) 1599 (s). Anal. Calc. for C88H120N22⋅ 1/2CH2Cl2: C, 69.54; 
H, 7.98; N, 20.16. Found: C, 69.24; H, 8.18; N, 20.49%. 
 
 
7.2.2 Metalla-dendrimers, compounds 1-4 
 
N
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N
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General synthesis for metalla-dendrimers 
The dimer ([(η6-p-iPrC6H4Me))RuCl2]2 (0.35 mmol, 0.213 g) for 1, (0.307 mmol, 
0.187 g) for 3 and [(η6-C6Me6))RuCl2]2 (0.081 mmol, 0.054 g) for 2, (0.248 mmol, 0.165 
g) for 4) was dissolved in dry CH2Cl2 (30 mL). To this was added a solution of the 
dendritic ligand in CH2Cl2 (5 mL) (G1 (0.17 mmol, 0.117 g) for 1, (0.041 mmol, 0.027 g) 
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for 2, and G2 (0.077 mmol, 0.114 g) for 3 and (0.062 mmol, 0.092 g) for 4). The reaction 
mixture was stirred at room temperature for 5 h. The solvent was then reduced to 3 mL, 
and the product was precipitated with petroleum ether. The resulting yellow–orange 
precipitate was filtered, washed with petroleum ether and dried in vacuo. 
 
 
[{(η6-p-iPrC6H4Me)RuCl2}4G1)] (1). Yield 0.26 g (79.1%). M.p.: 165 °C (decompose, 
without melting). 1H NMR (300 MHz, CDCl3): δ (ppm) = 9.06 (d, 8H, 3JH-H = 5.42 Hz, 
Har), 8.20 (s, 4H, imine), 7.49 (d, 8H, 3JH-H = 6.15 Hz, Har), 5.70 (d, 8H, 3JH-H = 5.70 Hz, 
Har), 5.28 (d, 8H, 3JH-H = 6.09 Hz, Har), 3.67 (m, 8H, H5), 2.97 (m, 4H, CHMe2), 2.44–
2.97 (overlapping m, 12H, H2, H3), 2.09 (s, 12H, CH3), 1.83 (br m, 8H, CH2), 1.47 (br m, 
4H, CH2), 1.30 (d, 24H, 3JH-H = 6.87 Hz, CHMe2). 13C{1H} NMR (100 MHz, CDCl3): δ 
(ppm) = 158.4 (CH, imine), 139.8 (C, pyr), 155.3 (CH, pyr), 122.5, 103.3 (C, p-cym), 
97.5, 83.3 (CH, p-cym), 82.1, 58.8 (CH2), 53.7, 51.2, 31.5, 30.7, 27.1, 22.3 (CH3, p-cym), 
18.3. IR (NaCl cells, CH2Cl2, cm-1): ν(imine, C=N) 1646 (s), ν(pyr, C=N) 1615 (s). Anal. Calc. 
for C80H108Ru4Cl8N10⋅11/2CH2Cl2: C, 48.34; H, 5.52; N, 6.92. Found: C, 48.22; H, 5.15; 
N, 6.74%. MS (ESI, m/z): 565.0 [M + 4H + 4CH2Cl2 + H2O]4+. 
 
 
 
[{(η6-C6Me6)RuCl2}4G1] (2). Yield 0.050 g (86.5%). M.p.: 188 °C (decompose, without 
melting). 1H NMR (300 MHz, CDCl3): δ (ppm) = 8.78 (d, 8H, 3JH-H = 6.3 Hz, Har), 8.23 
(s, 4H, imine), 7.51 (d, 8H, 3JH-H = 6.4 Hz, Har), 3.67 (m, 8H, CH2), 2.49–2.58 
(overlapping m, 12H, CH2), 1.97 (s, 72H, CH3), 1.85 (br m, 8H, CH2), 1.44 (br m, 4H, 
CH2). 13C{1H} NMR (75 MHz, CDCl3): δ (ppm) = 158.9 (CH, imine), 155.0 (CH, pyr), 
143.9 (C, pyr), 122.5, 91.4 (C, HMB), 58.2 (CH2), 53.4, 51.0, 26.2, 24.2, 15.4 (CH3, 
HMB). IR (NaCl cells, CH2Cl2, cm-1): ν(imine, C=N) 1646 (s), ν(pyr, C=N) 1614 (s). Anal. Calc. 
for C88H124Ru4Cl8N10⋅CH2Cl2: C, 51.03; H, 6.06; N, 6.69. Found: C, 51.01; H, 5.85; N, 
6.39%. MS (ESI, m/z): 635.0 [M-3Cl]3+
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[{(η6-p-iPrC6H4Me)RuCl2}8G2] (3). Yield 0.30 g (98.1%). M.p.: 214 °C (decompose, 
without melting). 1H NMR (300 MHz, CDCl3): δ (ppm) = 9.05 (d, 16H, 3JH-H = 6.53 Hz, 
Har), 8.19 (s, 8H, imine), 7.49 (d, 16H, 3JH-H = 6.61 Hz, Har), 5.49 (d, 16H, 3JH-H = 6.01 
Hz, Har), 5.28 (d, 16H, 3JH-H = 6.02 Hz, Har), 3.67 (m, 16H, CH2), 2.97 (m, 8H, CHMe2), 
2.30–2.53 (overlapping m, 36H, CH2), 2.09 (s, 24H, CH3), 1.78 (m, 16H, CH2), 1.35–
1.48 (overlapping m, 12H, CH2), 1.32 (d, 48H, 3JH-H = 6.92 Hz, CHMe2). 13C{1H} NMR 
(75 MHz, CDCl3): δ (ppm) = 158.3 (CH, imine), 155.3 (CH, pyr), 144.2 (C, pyr), 122.5, 
103.2 (C, p-cym), 97.4, 83.0 (CH, p-cym), 82.0, 58.8 (CH2), 55.2, 51.4, 38.8, 30.6, 27.1, 
22.2 (CH3, p-cym), 18.2. IR (NaCl cells, CH2Cl2, cm-1): ν(imine, C=N) 1646 (s), ν(pyr, C=N) 
1614 (s). Anal. Calc. for C168H232Ru8Cl16N22⋅4CH2Cl2: C, 48.32; H, 5.66; N, 7.21. Found: 
C, 48.37; H, 6.03; N, 6.61%. MS (ESI, m/z): 569.0 [M-7Cl + 3CH2Cl2 + CH3CN]7+. 
 
 
[{(η6-C6Me6)RuCl2}8G2] (4). Yield 0.23 g (91.7%). M.p.: 194 °C (decompose, without 
melting). 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.78 (d, 16H, 3JH-H = 5.6 Hz, Har), 8.23 
(s, 8H, imine), 7.54 (d, 16H, 3JH-H = 6.0 Hz, Har), 3.69 (m, 16H, CH2), 2.60 (m, 16H, 
CH2), 2.50 (m, 4H, CH2,), 2.15–2.38 (overlapping m, 24H, CH2), 1.99 (s, 144H, CH3), 
1.87 (m, 8H, CH2), 1.63 (br m, 8H, CH2), 1.31 (br m, 4H, CH2). 13C{1H} NMR (100 
MHz, CDCl3): δ (ppm) = 158.9 (C, imine), 155.0 (CH, pyr), 144.1 (C, pyr), 122.5, 91.4 
(C, HMB), 25.3–58.9 (CH2), 15.4 (CH3, HMB). IR (NaCl cells, CH2Cl2, cm-1): ν(imine, C=N) 
1646 (s), ν(pyr, C=N) 1613 (s). Anal. Calc. for C184H264Ru8Cl16N22⋅2CH2Cl2: C, 51.60; H, 
6.24; N, 7.12. Found: C, 51.69; H, 6.43; N, 6.82%. MS (ESI, m/z): 631.0 [M-7Cl + 
5CH2Cl2 + 2CH3CN]7+. 
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7.2.3 Mononuclear compounds 5-6 
 
 
 
General synthesis of mononuclear reference compounds 
The N-(pyridin-4-ylmethylene)propan-1-amine (L), was prepared by the reaction 
of 4-pyridinecarboxaldehyde (0.107 g, 0.723 mmol for 5; 0.030 g, 0.200 mmol for 6) 
with n-propylamine in Et2O. The dimer ([(η6-p-iPrC6H4Me)RuCl2]2 (0.223 g, 0.362 
mmol) for 5 and [(η6-C6Me6)RuCl2]2 (0.068 g, 0.100 mmol) for 6) was dissolved in dry 
CH2Cl2 (30 mL). A solution of the N-(pyridin-4-ylmethylene)propan-1-amine (0.107 g, 
0.723 mmol) in dry CH2Cl2 (5 mL) was added dropwise and the reaction mixture was 
stirred for 5 hours. The solvent was then reduced to 3 mL and the product was 
precipitated with petroleum ether. The orange-yellow precipitate was filtered, washed 
with petroleum ether and dried in vacuo. 
 
 
[(η6-p-iPrC6H4Me)RuCl2(L)] (5). Yield 0.15 g (91.1%). M.p.: 163-166 °C. 1H NMR 
(400 MHz, CDCl3): δ (ppm) = 9.10 (d, 2H, 3JH-H = 6.43 Hz, Har). 8.27 (s, 1H, imine), 
7.60 (d, 2H, 3JH-H = 6.53 Hz, Har), 5.45 (d, 2H, 3JH-H = 5.92 Hz, Har), 5.23 (d, 2H, 3JH-H = 
5.93 Hz, Har), 3.66 (t, 2H, 3JH-H = 6.47 Hz, CH2), 3.00 (m, 1H, CHMe2), 2.11 (s, 3H, 
CH3), 1.75 (m, 2H, CH2), 1.32 (d, 6H, 3JH-H = 6.93 Hz, CHMe2), 0.97 (t, 3H, 3JH-H = 7.39 
Hz, CH3). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 157.3 (CH, imine), 155.3 (CH, 
pyr), 144.6 (C, pyr), 122.5, 103.6 (C, p-cym), 97.3, 83.1 (CH, p-cym), 82.2, 63.6 (CH2), 
30.7, 23.8, 22.3 (CH3, p-cym), 18.2, 11.8 (CH3). IR (NaCl cells, CH2Cl2, cm-1): ν(imine, C=N) 
1647 (s), ν(pyr, C=N) 1615 (s). Anal. Calc. for C19H26RuCl2N2: C, 50.22; H, 5.77; N, 6.16. 
Found: C, 49.96; H, 5.38; N, 5.99%. MS (ESI, m/z): 419.1 [M-Cl]+. 
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[(η6-C6Me6)RuCl2(L)] (6). Yield 0.15 g (91.1%). M.p.: 139 °C (decompose, without 
melting). 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.86 (d, 2H, 3JH-H = 6.2 Hz, Har), 8.26 
(s, 1H, imine), 7.57 (d, 2H, 3JH-H = 6.4 Hz, Har), 3.66 (t, 2H, 3JH-H = 6.9 Hz, CH2), 2.03 (s, 
18H, CH3), 1.74 (m, 2H, CH2), 0.96 (t, 3H, 3JH-H = 7.4 Hz, CH3). 13C{1H} NMR (100 
MHz, CDCl3): δ (ppm) = 157.5 (CH, imine), 155.1 (CH, pyr), 144.2 (C, pyr), 122.5, 91.4 
(C, HMB), 63.6 (CH2), 23.8, 15.4 (CH3, HMB), 11.8 (CH3). IR (NaCl cells, CH2Cl2, cm-
1): ν(imine, C=N) 1646 (s), ν(pyr, C=N) 1614 (s). Anal. Calc. for C21H30RuCl2N2: C, 52.28; H, 
6.27; N, 5.81. Found: C, 51.84; H, 5.94; N, 5.47%. MS (ESI, m/z): 447.1 [M-Cl]+. 
 
 
Cytotoxicity study on metalla-dendrimers 
While imine bonds are susceptible to hydrolysis, the presence of the aromatic 
substituent together with a possible dendrimer effect reduces the rate of hydrolysis, and 
for the compounds studied herein only a slow decomposition is observed. The human 
A2780 ovarian cancer cell line was obtained from the European Collection of Cell 
Cultures (Salisbury, UK). Cells were grown routinely in RPMI medium containing 
glucose, 5% foetal calf serum (FCS) and antibiotics at 37 °C and 5% CO2. Cytotoxicity 
was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide). Cells were seeded in 96-well plates as monolayers with 100 μL 
of cell solution (approximately 20,000 cells) per well and pre-incubated for 24 hours in 
medium supplemented with 10% FCS. Compounds were prepared as DMSO solution 
then dissolved in the culture medium and serially diluted to the appropriate concentration, 
to give a final DMSO concentration of 0.5%. One hundred micro liter of drug solution 
was added to each well and the plates were incubated for another 72 h. Subsequently, 
MTT (5 mg/mL solution) was added to the cells and the plates were incubated for a 
further 2 h. The culture medium was aspirated, and the purple formazan crystals formed 
by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The 
optical density, directly proportional to the number of surviving cells, was quantified at 
540 nm using a multiwell plate reader and the fraction of surviving cells was calculated 
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from the absorbance of untreated control cells. Evaluation is based on means from two 
independent experiments, each comprising 3 microcultures per concentration level. 
 
 
7.2.4 Bimetallic molecular clip, compounds 7-10 
 
 
General synthesis of bimetallic molecular clips 
A mixture of [(η6-arene)RuCl2]2 ([(η6-p-iPrC6H4Me)RuCl2]2 (184 mg, 0.3 mmol) 
for 7 and 8 and [(η6-C6Me6)RuCl2]2 (201 mg, 0.3 mmol) for 9 and 10) and the quinone 
(2,5-dihydroxy-1,4-benzoquinone (dhbq-H2) (42 mg, 0.3 mmol) for 7 and 9 and 
chloranillic acid (dchq-H2) (63 mg, 0.3 mmol) for 8 and 10) was suspended in MeOH (30 
mL) and stirred for 2 h at room temperature. The precipitate was filtered, washed with 
Et2O, and dried in vacuo. 
 
[(η6-p-iPrC6H4Me)2Ru2(dhbq)Cl2] (7). Yield: 165 mg (81%). 1H NMR (400 MHz, 
CDCl3): δ (ppm) = 5.82 (s, 2H, Hq), 5.66 (d, 4H, 3JH-H = 6.12 Hz, Har), 5.41 (d, 4H, Har), 
2.97 (sept, 2H, 3JH-H = 6.72 Hz, CH), 2.32 (s, 6H, CH3), 1.35 (d, 12H, CH3). 13C{1H} 
NMR (100 MHz, CDCl3): δ (ppm) = 184.45, 139.12, 119.46, 102.29, 97.03, 81.55, 79.60, 
31.70, 22.87, 19.09. IR (cm-1): 1528(s), 1377(s), 1257(s). Anal. Calc. for 
C26H30Cl2O4Ru2: C, 45.90; H, 4.45. Found: C, 45.72; H, 4.60%. 
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[(η6-p-iPrC6H4Me)2Ru2(dchq)Cl2] (8). Yield: 165 mg (74%). 1H NMR (400 MHz, 
CDCl3): δ (ppm) = 5.74 (d, 4H, 3JH-H = 6.20 Hz, Har), 5.48 (d, 4H, Har), 2.98 (sept, 2H, 
3JH-H = 7.00 Hz, CH), 2.34 (s, 6H, CH3), 1.36 (d, 12H, CH3). 13C{1H} NMR (100 MHz, 
CDCl3): δ (ppm) = 184.72, 137.45, 118.41, 102.36, 98.62, 82.07, 76.44, 31.72, 21.53, 
18.59. IR (cm-1): 1639(s), 1496(s), 1370(s). Anal. Calc. for C26H28O4Cl4Ru2: C, 41.70; H, 
3.77. Found: C, 41.61; H, 3.82%. 
 
 
[(η6-C6Me6)Ru2(dhbq)Cl2] (9). Yield: 170 mg (77%). 1H NMR (400 MHz, CDCl3): δ 
(ppm) = 5.90 (s, 2H, Hq), 2.17 (s, 36H, CH3). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) 
= 182.96, 114.62, 105.88, 90.55, 16.24. IR (cm-1): 1638(s), 1617(s), 1551(s), 1532(m), 
1374(m), 1255(s), 620(s). Anal. Calc. for C30H38O4Cl2Ru2: C, 48.98; H, 5.20. Found: C, 
48.77; H, 5.94%. 
 
 
[(η6-C6Me6)Ru2(dchq)Cl2] (10). Yield: 185 mg (77%). 1H NMR (200 MHz, CDCl3): δ 
(ppm) = 2.02 (s, 36H, CH3). 13C{1H} NMR (100 MHz, CDCl3): δ (ppm) = 184.53, 
126.27, 107.36, 92.64, 15.18. IR (cm-1): 1638(s), 1617(s), 1499(m), 1363(m), 1111(m), 
620(s). Anal. Calc. for C30H36O4Cl4Ru2: C, 44.79; H, 4.51. Found: C, 44.89; H, 4.73%. 
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7.2.5 Supramolecular rectangles, compounds 11-22 
 
General synthetic method for supramolecular rectangles [11-22][O3SCF3]4  
A mixture of 7-10 (0.1 mmol) and 2 equiv of AgO3SCF3 (0.2 mmol) in MeOH (20 
mL) was stirred at room temperature for 2 h and then filtered to remove AgCl. To the red 
filtrate, the corresponding N∩N ligand (0.1 mmol) was added. The mixture was stirred at 
room temperature for 24 h, the solvent was then removed under vacuum. The residue was 
taken up in CH2Cl2 (20 mL), the extract was then filtered and concentrated (3 mL), Et2O 
was slowly added to precipitate the product as a dark orange or red solid. 
 
 
[(η6-p-iPrC6H4Me)4Ru4(pyrazine)2(dhbq)2][O3SCF3]4 ([11][O3SCF3]4). Yield: 71 mg 
(72%). 1H NMR(400 MHz, acetone-d6): δ (ppm) = 8.70 (s, 8H, CHpyz), 6.21 (d, 8H, 3JH-H 
= 6.4 Hz, Har), 6.05 (d, 8H, 3JH-H = 6.4 Hz, Har), 5.64 (s, 4H, Hq), 2.96 (sep, 4H, 3JH-H = 
7.0 Hz, CH), 2.35 (s, 12H, CH3), 1.39 (d, 24H, 3JH-H = 7.0 Hz, CH3). 13C{1H} NMR (100 
MHz, acetone-d6): δ (ppm) = 184.8 (C=O), 149.9 (CHpyz), 104.8 (Cp-cym), 102.1 (CHq), 
98.5 (Cp-cym), 83.8 (CHp-cym), 83.2 (CHp-cym), 31.1 (CH(CH3)2), 21.1 (CH3), 16.5 
(CH(CH3)2). IR (cm-1): 1637(w), 1529(s), 1377(m), 1259(s), 1227(w), 1162(m), 1030(m), 
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635(w). Anal. Calc. for C64H68N4O20F12S4Ru4: C, 38.95; H, 3.47; N, 2.84. Found: C, 
38.73; H, 3.44; N, 2.78%. 
 
 
[(η6-p-iPrC6H4Me)4Ru4(pyrazine)2(dchq)2][O3SCF3]4 ([12][O3SCF3]4). Yield: 71 mg 
(68%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.75 (s, 8H, CHpyz), 6.30 (d, 8H, 3JH-H 
= 6.4 Hz, Har), 6.14 (d, 8H, 3JH-H = 6.4 Hz, Har), 3.06 (sep, 4H, 3JH-H = 6.9 Hz, CH), 2.44 
(s, 12H, CH3), 1.46 (d, 24H, 3JH-H = 6.9 Hz, CH3). 13C{1H} NMR (100 MHz, acetone-d6): 
δ (ppm) = 177.9 (C=O), 150.3 (CHpyz), 106.1 (Cp-cym), 104.5 (CClq), 98.8 (Cp-cym), 84.1 
(CHp-cym), 83.9 (CHp-cym), 31.3 (CH(CH3)2), 21.4 (CH3), 17.3 (CH(CH3)2). IR (cm-1): 
1627(w), 1504(s), 1373(s), 1266(s), 1225(w), 1163(m), 1029(m), 637(m). Anal. Calc. for 
C64H64Cl4N4O20F12S4Ru4⋅3CH2Cl2: C, 35.54; H, 3.03; N, 2.55. Found: C, 35.08; H, 3.17; 
N, 2.69%. 
 
 
[(η6-C6Me6)4Ru4(pyrazine)2(dhbq)2][O3SCF3]4 ([13][O3SCF3]4). Yield: 88 mg (83%). 
1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.70 (s, 8H, CHpyz), 5.72 (s, 4H, Hq), 2.20 (s, 
72H, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 183.9 (C=O), 148.0 
(CHpyz), 101.7 (CHq), 93.7 (Chmb), 14.6 (CH3). IR (cm-1): 1628(w), 1527(s), 1374(s), 
1257(s), 1224(w), 1156(m), 1031(m), 638(m). Anal. Calc. for C72H84N4O20F12S4Ru4 
⋅3CH2Cl2: C, 40.39; H, 3.99; N, 2.58. Found: C, 39.85; H, 4.01; N, 2.70%. 
 
 
[(η6-C6Me6)4Ru4(pyrazine)2(dchq)2][O3SCF3]4 ([14][O3SCF3]4). Yield: 82 mg (75%). 
1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.71 (s, 8H, CHpyz), 2.21 (s, 72H, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 183.8 (C=O), 148.0 (CHpyz), 105.3 
(CClq), 93.7 (Chmb), 14.6 (CH3). IR (cm-1): 1626(w), 1504(s), 1372(m), 1260 (m) 
1158(w), 1031(m), 638(w). Anal. Calc. for C72H80Cl4N4O20F12S4Ru4: C, 38.89; H, 3.63; 
N, 2.52. Found: C, 38.63; H, 3.77; N, 2.45%. 
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[(η6-p-iPrC6H4Me)4Ru4(4,4’-bipyridine)2(dhbq)2][O3SCF3]4 ([15][O3SCF3]4). Yield: 
79 mg (74%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.54 (d, 8H, 3JH-H = 4.4 Hz, 
CHbpy), 8.02 (d, 8H, 3JH-H = 4.4 Hz, CHbpy), 6.20 (d, 8H, 3JH-H = 8.0 Hz, Har), 5.99 (d, 8H, 
3JH-H = 8.0 Hz, Har), 5.79 (s, 4H, Hq), 2.95 (sep, 4H, 3JH-H = 8.0 Hz, CH), 2.21 (s, 12H, 
CH3), 1.38 (d, 24H, 3JH-H = 8.0 Hz, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) 
= 174.3 (C=O), 154.0 (CHbpy), 144.7 (Cbpy), 123.6 (CHbpy), 103.7 (Cp-cym), 101.7 (CHq), 
99.3 (Cp-cym), 83.9 (CHp-cym), 82.1 (CHp-cym), 31.2 (CH(CH3)2), 21.6 (CH3), 17.2 
(CH(CH3)2). IR (cm-1): 1637(s), 1616(s), 1526(m), 1378(s), 1259(m), 1159(s), 1030(s), 
636(s). Anal. Calc. for C76H76N4O20F12S4Ru4: C, 42.94; H, 3.60; N, 2.64. Found: C, 
42.91; H, 3.87; N, 2.61%. 
 
 
[(η6-p-iPrC6H4Me)4Ru4(4,4’-bipyridine)2(dchq)2][O3SCF3]4 ([16][O3SCF3]4). Yield: 86 
mg (75%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.54 (d, 8H, 3JH-H = 6.4 Hz, 
CHbpy), 8.06 (d, 8H, 3JH-H = 6.4 Hz, CHbpy), 6.28 (d, 8H, 3JH-H = 6.4 Hz, Har), 6.11 (d, 8H, 
3JH-H = 6.4 Hz, Har), 2.99 (sep, 4H, 3JH-H = 6.8Hz, CH), 2.34 (s, 12H, CH3), 1.42 (d, 24H, 
3JH-H = 6.8 Hz, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 178.5 (C=O), 
154.8 (CHbpy), 145.6 (Cbpy), 124.6 (CHbpy), 107.0 (Cp-cym), 104.8 (CClq), 100.1 (Cp-cym), 
84.9 (CHp-cym), 83.8 (CHp-cym), 32.2 (CH(CH3)2), 22.5 (CH3), 18.2 (CH(CH3)2). IR (cm-1): 
1637(s), 1617(s), 1502(m), 1374(m), 1259(s), 1163(m), 1031(s), 638(s). Anal. Calc. for 
C76H72N4O20F12S4Cl4Ru4: C, 40.32; H, 3.21; N, 2.47. Found: C, 40.85; H, 3.32; N, 
2.36%. 
 
 
[(η6-C6Me6)4Ru4(4,4’-bipyridine)2(dhbq)2][O3SCF3]4 ([17][O3SCF3]4). Yield: 60 mg 
(54%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.39 (d, 8H, 3JH-H = 5.3 Hz, CHbpy), 
8.08 (d, 8H, 3JH-H = 5.3 Hz, CHbpy), 5.76 (s, 4H, Hq), 2.16 (s, 72H, CH3). 13C{1H} NMR 
(100 MHz, acetone-d6): δ (ppm) = 175.2 (C=O), 153.4 (CHbpy), 144.1 (Cbpy), 123.6 
(CHbpy), 101.7 (CHq), 93.6 (Chmb), 14.7 (CH3). IR (cm-1): 1638(s), 1617(s), 1525(s), 
1375(m), 1258(s), 1162(m), 1032(s), 622(s). Anal. Calc. for C84H92N4O20F12S4Ru4: C, 
45.08; H, 4.14; N, 2.50. Found: C, 45.01; H, 4.14; N, 2.32%. Crystals suitable for X-ray 
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diffraction analysis were obtained by slow diffusion of Et2O in an acetone solution of 
[17][O3SCF3]4. 
 
 
[(η6-C6Me6)4Ru4(4,4’-bipyridine)2(dchq)2][O3SCF3]4 ([18][O3SCF3]4). Yield: 86 mg 
(73%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.40 (dd, 8H, 3JH-H = 5.4 Hz, 4JH-H = 
1.5 Hz, CHbpy), 8.13 (dd, 8H, 3JH-H = 5.4 Hz, 4JH-H = 1.5 Hz, CHbpy), 2.18 (s, 72H, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 177.5 (C=O), 153.8 (CHbpy), 144.6 
(Cbpy), 126.7 (CHbpy), 106.4 (CClq), 94.4 (Chmb), 15.2 (CH3). IR (cm-1): 1637(s), 1617(s), 
1499(s), 1369(m), 1259(s), 1161(m), 1032(s), 638(s). Anal. Calc. for 
C84H88N4O20F12S4Cl4Ru4: C, 42.46; H, 3.73; N, 2.36. Found: C, 42.44; H, 3.23; N, 
2.32%. 
 
 
[(η6-p-iPrC6H4Me)4Ru4{1,2-bis(4-pyridyl)ethylene}2(dhbq)2][O3SCF3]4 
([19][O3SCF3]4). Yield: 87 mg (80%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.35 
(d, 8H, 3JH-H = 6.6 Hz, CHbpe), 7.74 (d, 8H, 3JH-H = 6.6 Hz, CHbpe), 7.63 (s, 4H, CHbpe), 
6.17 (d, 8H, 3JH-H = 6.4Hz, Har), 5.98 (d, 8H, 3JH-H = 6.4 Hz, Har), 5.78 (s, 4H, Hq), 2.96 
(sep, 4H, 3JH-H = 7.1 Hz, CH), 2.23 (s, 12H, CH3), 1.36 (d, 24H, 3JH-H = 7.1 Hz, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.2 (C=O), 153.2 (CHbpe), 146.1 
(Cbpe), 131.7 (CHbpe), 123.9 (CHbpe), 103.7 (Cp-cym), 101.7 (CHq), 99.0 (Cp-cym), 83.7 
(CHp-cym), 82.1 (CHp-cym), 31.2 (CH(CH3)2), 21.6 (CH3), 17.2 (CH(CH3)2). IR (cm-1): 
1638(s), 1616 (s), 1525(s), 1378(m), 1259(m), 1161(m), 1031(m), 636(s). Anal. Calc. for 
C80H80N4O20F12S4Ru4: C, 44.12; H, 3.70; N, 2.57. Found: C, 44.06; H, 3.86; N, 2.55%. 
 
 
[(η6-p-iPrC6H4Me)4Ru4{1,2-bis(4-pyridyl)ethylene}2(dchq)2][O3SCF3]4 
([20][O3SCF3]4). Yield: 85 mg (74%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.32 
(dd, 8H, 3JH-H = 5.4 Hz, 4JH-H = 1.4 Hz, CHbpe), 7.77 (dd, 8H, 3JH-H = 5.4 Hz, 4JH-H = 1.4 
Hz, CHbpe), 7.69 (s, 4H, CHbpe), 6.25 (d, 8H, 3JH-H = 6.4 Hz, Har), 6.08 (d, 8H, 3JH-H = 6.4 
Hz, Har), 3.03 (sep, 4H, 3JH-H = 7.0 Hz, CH), 2.32 (s, 12H, CH3), 1.42 (d, 24H, 3JH-H = 7.0 
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Hz, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 178.0 (C=O), 153.3 (CHbpe), 
146.4 (Cbpe), 132.0 (CHbpe), 124.2 (CHbpe), 106.2 (Cp-cym), 104.0 (CClq), 99.0 (Cp-cym), 
83.9 (CHp-cym), 82.9 (CHp-cym), 31.4 (CH(CH3)2), 21.7 (CH3), 17.4 (CH(CH3)2). IR (cm-1): 
1638(s), 1619(s), 1501(s), 1373(m), 1258(s), 1163(m), 1031(m), 638(s). Anal. Calc. for 
C80H76N4O20F12S4Cl4Ru4: C,41.49; H, 3.31; N, 2.42. Found: C, 41.43; H, 3.49; N, 2.26%. 
 
 
[(η6-C6Me6)4Ru4{1,2-bis(4-pyridyl)ethylene}2(dhbq)2][O3SCF3]4 ([21][O3SCF3]4). 
Yield: 93 mg (83%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.20 (dd, 8H, 3JH-H = 
5.4 Hz, 4JH-H = 1.4 Hz, CHbpe), 7.76 (dd, 8H, 3JH-H = 5.4 Hz, 4JH-H = 1.4 Hz, CHbpe), 7.59 
(s, 4H, CHbpe), 5.76 (s, 4H, Hq), 2.15 (s, 72H, CH3). 13C{1H} NMR (100 MHz, acetone-
d6): δ (ppm) = 184.6 (C=O), 153.5 (CHbpe), 146.9 (Cbpe), 132.6 (CHbpe), 125.2 (CHbpe), 
102.7 (CHq), 94.3 (Chmb), 15.6 (CH3). IR (cm-1): 1638(s), 1617(s), 1524(m), 1374(m), 
1257(m), 1112(m), 1031(m), 621(s). Anal. Calc. for C88H96N4O20F12S4Ru4: C, 46.15; H, 
4.22; N, 2.45. Found: C, 46.32; H, 4.46; N, 2.29%. 
 
 
[(η6-C6Me6)4Ru4{1,2-bis(4-pyridyl)ethylene}2(dchq)2][O3SCF3]4 ([22][O3SCF3]4). 
Yield: 80 mg (66%). 1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.19 (dd, 8H, 3JH-H = 6.6 
Hz, 4JH-H = 1.2 Hz, CHbpe), 7.80 (dd, 8H, 3JH-H = 6.6 Hz, 4JH-H = 1.2 Hz, CHbpe), 7.67 (s, 
4H, CHbpe), 2.18 (s, 72H, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 177.5 
(C=O), 152.6 (CHbpe), 146.2 (Cbpe), 131.9 (CHbpe), 124.4 (CHbpe), 106.0 (CClq), 93.7 
(Chmb), 14.7 (CH3). IR (cm-1): 1638(s), 1617(s), 1498(s), 1370(m), 1164(m), 1031(m), 
623(s). Anal. Calc. for C88H92N4O20F12S4Cl4Ru4: C, 43.53; H, 3.82; N, 2.31. Found: C, 
43.92; H, 3.94; N, 2.25%. Crystals suitable for X-ray diffraction analysis were obtained 
by slow diffusion of Et2O in an acetone solution of [22][O3SCF3]4. 
 
 
Cytotoxicity study of supramolecular rectangles 
The human A2780 ovarian cancer cell line was obtained from the European 
Collection of Cell Cultures (Salisbury, UK). Cells were grown routinely in RPMI 
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medium containing glucose, 5% fetal calf serum (FCS), and antibiotics at 37 °C and 5% 
CO2. Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were seeded in 96-well plates as 
monolayers with 100 μL of cell solution (approximately 20 000 cells) per well and 
preincubated for 24 h in medium supplemented with 10% FCS. Compounds were 
predissolved in DMSO, then added to the culture medium (to give a final DMSO 
concentration of 0.5%) and serially diluted to the appropriate concentration; 100 μL of 
drug solution was added to each well, and the plates were incubated for another 72 h. 
Subsequently, MTT (5 mg/mL solution) was added to the cells, and the plates were 
incubated for a further 2 h. The culture medium was aspirated, and the purple formazan 
crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved 
in DMSO. The optical density, directly proportional to the number of surviving cells, was 
quantified at 540 nm using a multiwell plate reader, and the fraction of surviving cells 
was calculated from the absorbance of untreated control cells. Evaluation is based on 
means from two independent experiments, each comprising 3 microcultures per 
concentration level. 
 
 
7.2.5 Pyrenyl derivatives 
 
 
 
 
 
Synthesis of pyrenyl ethacrynic amide (g) 
Ethacrynic acid (0.23 g, 0.756 mmol) was suspended in oxalyl chloride (5 mL) 
and refluxed for 1 h. The unreacted oxalyl chloride was removed by reduced pressure. A 
suspension of methylamine pyrene (0.202 g, 0.756 mmol) and Et3N (0.75 mL, 5.3 mmol) 
in THF (50 mL) was added dropwise to the ethacrynic acid chloride. The mixture was 
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then stirred at 60°C for 18 h. The solvent was removed by reduced pressure and the 
product re-dissolved in CHCl3. The solution was filtered and the filtrate was washed with 
NaHCO3 solution and thereafter brine, dried over MgSO4 and the solvent evaporated to 
give an oil which was purified on silica gel column, mobile phase CH2Cl2:acetone 3:1, to 
give the product as a pale yellow powder. Yield: 163 mg (39%).  
 
 
Pyrenyl ethacrynic amide (g). 1H NMR (400 MHz, CD2Cl2): δ (ppm) = 8.32 (d, 1H, 3JH-
H = 9.24 Hz, Hpy), 8.24 (m, 2H, Hpy), 8.20 (d, 1H, 3JH-H = 2.24 Hz, Hpy), 8.18 (s, 1H, Hpy), 
8.07 (m, 4H, Hpy), 7.18 (s, 1H, NH), 7.12 (d, 1H, 3JH-H = 8.52 Hz, Har), 6.89 (d, 1H, 3JH-H 
= 8.55 Hz, Har), 5.85 (t, 1H, 3JH-H = 1.38 Hz, Hc=c), 5.42 (s, 1H, Hc=c), 5.28 (d, 2H, 3JH-H = 
5.80 Hz, Py-CH2-NH), 4.68 (s, 2H, CO-CH2-O), 2.40 (q, 2H, 3JH-H = 7.41 Hz, C-CH2-
CH3), 1.10 (t, 3H, 3JH-H = 7.44 Hz, CH3). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm) = 
206.5, 195.4, 166.5, 154.7, 150.2, 134.2, 131.4, 131.3, 131.0, 130.8, 128.9, 128.7, 128.3, 
127.6, 127.4, 127.3, 126.9, 126.3, 125.6, 125.5, 125.0, 125.0, 124.7, 122.7, 111.3, 68.7, 
41.4, 30.7, 23.4, 12.3. IR (cm-1): 3427(br), 3267(m), 1653(vs), 1586(m), 1564(m), 
1466(m), 1382(w), 1251(m), 1124(w), 1089(m), 998(w), 849(s), 841(m), 827(w), 
797(w), 714(w). MS (ESI, m/z): 553.6 [M(2× 35Cl)+K]+, 555.6 [M(35Cl, 37Cl)+K]+, 557.6 
[M(2× 37Cl)+K]+. 
 
 
 
 
 
 
Synthesis of 2-(Pyren-1-ylmethylcarbamoyl) phenyl acetate (h) 
Aspirin (150 mg, 0.83 mmol) was suspended in thionyl chloride (20 mL) and 
stirred for 4 h at room temperature. Thionyl chloride was removed by reduced pressure 
and then a mixture of 1-pyrenemethylamine (223 mg, 0.83 mmol) and Et3N (0.12 mL, 
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0.85 mmol) in THF (50 mL) was slowly added. The mixture was stirred at 60°C for 18 h. 
The solvent was removed by reduced pressure and the product re-dissolved in CHCl3. 
The solution was filtered and the filtrate washed with NaHCO3 solution and thereafter 
brine, dried over MgSO4 and then the solvent evaporated to give an oil which was 
purified on silica gel column, mobile phase CH2Cl2:acetone 3:1, to give the product as a 
pale yellow powder. Yield: 50 mg (15%). 
 
2-(Pyren-1-ylmethylcarbamoyl) phenyl acetate (h). 1H NMR (400 MHz, CD2Cl2): δ 
(ppm) = 8.33 (d, 1H, 3JH-H = 9.25 Hz, Hpy), 8.21 (m, 4H, Hpy), 8.06 (m, 4H, Hpy), 7.38 
(ddd, 1H, 3JH-H = 7.81 Hz, 4JH-H = 1.52 Hz, Har), 7.32 (dd, 1H, 3JH-H = 8.02 Hz, 4JH-H = 
1.51 Hz, Har), 6.97 (dd, 1H, 3JH-H = 8.38 Hz, 4JH-H = 1.02 Hz, Har), 6.78 (ddd, 1H, 3JH-H = 
7.62 Hz, 4JH-H = 1.17 Hz, Har), 6.75 (br, 1H, NH), 5.35 (d, 2H, 3JH-H = 5.37 Hz, Py-CH2-
NH), 1.27 (s, 3H, CH3). 13C{1H} NMR (100 MHz, CD2Cl2): δ (ppm) = 169.8, 161.8, 
134.4, 131.5, 131.4, 130.8, 130.5, 129.2, 128.5, 127.7, 127.421, 127.3, 126.3, 125.6, 
125.5, 125.1, 124.9, 124.7, 122.7, 118.7, 118.5, 114.2, 42.0, 29.8. IR (cm-1): 3332(w), 
1635(m), 1583(s), 1537(s), 1493(m), 1443(w), 1356(s), 1300(m), 1246(m), 1229(m), 
1216(s), 1033(w), 847(s), 817(w), 758(m), 721(w), 704(w). MS (ESI, m/z): 350.3 [(M-
CH2CO)-H]-.  
 
 
 
Synthesis of 1,8-Bis(3-methyl-butyn-1-yl-3-ol)pyrene (i)  
This procedure follows a published method [144]. A Schlenk flask was charged 
with a solution of 2-methyl-but-3-yn-2-ol (1 mL, 10.3 mmol) in freshly distilled 
diethylamine (60 mL). The solution was freeze–pump–thaw degassed and transferred to a 
mixture of 1,6- and 1,8-diiodo pyrene (2.0 g, 4.4 mmol), Pd[PPh3]2Cl2 (68 mg), and CuI 
(0.12 mmol) under nitrogen atmosphere. The reaction mixture was heated at 50 °C under 
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nitrogen for 20 h. The solvent was removed under vacuum and the product was dissolved 
in CH2Cl2 and filtered. The filtrate was then evaporated and the crude product was 
purified using column chromatography, eluted with CH2Cl2:MeOH (1% MeOH). The 
product obtained as a yellow solid. Yield 0.1 g (6 %). 1H NMR (400 MHz CDCl3): δ 
(ppm) = 8.60 (s, 2H), 8.10 (s 4H), 8.04 (s, 2H), 1.81 (s, 12H). 
 
 
7.2.6 Supramolecular prismatic cages, compound 23-26 
 
 
 
 
General synthesis of supramolecular prisms 
A mixture of bimetallic clip [(η6-p-iPrC6H4Me)2Ru2(dhbq)Cl2] (60 mg, 0.09 
mmol) for 23, [(η6-p- PrCi 6H4Me)2Ru2 (dchq)Cl2] (67.5 mg, 0.09 mmol) for 24, [(η6-
C6Me6)2Ru2(dhbq)Cl2] (66.7 mg, 0.09 mmol) for 25 and [(η6-C6Me6)2Ru2(dchq)Cl2] (72.4 
mg, 0.09 mmol) for 26) and AgO3SCF3 (46 mg, 0.18 mmol) in MeOH (20 mL) was 
stirred at room temperature for 2 h, then filtered. To the red filtrate was added tpt (18.4 
122 
  Experimental Section   
mg, 0.06 mmol). The mixture was stirred at RT for 48 h, and the solvent removed under 
vacuum. The dark residue was taken up in CH2Cl2 (20 mL), and after filtration, the 
solution was concentrated (3 mL) and Et2O was added to precipitate a red solid. 
 
 
[(η6-p-iPrC6H4Me)6Ru6(tpt)2(dhbq)3][O3SCF3]6 ([23][O3SCF3]6). Yield: 75 mg (75%) 
1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.75 (dd, 12H, 3JH-H = 5.36 Hz, 4JH-H = 1.56 
Hz, Hα), 8.68 (dd, 12H, Hβ), 6.24 (d, 12H, 3JH-H = 6.32 Hz, Har), 6.03 (d, 12H, Har), 5.87 
(s, 6H, Hq), 3.00 (sept, 6H, 3JH-H = 6.92 Hz, CH), 2.28 (s, 18H, CH3), 1.41 (d, 36H, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 170.0, 154.8, 144.6, 125.1, 123.2, 
120.2, 104.4, 102.1, 99.5, 84.2, 82.7, 31.6, 22.0, 17.6. IR (cm-1): 1635(s), 1524(s), 
1377(m), 1259(s), 1161(m), 1031(m), 639(s). Anal. Calc. for C120H114N12O30F18S6Ru6: C, 
43.09; H, 3.44; N, 5.02. Found: C, 42.96; H, 3.33; N, 4.86%. 
 
 
 
[(η6-p-iPrC6H4Me)6Ru6(tpt)2(dchq)3][O3SCF3]6 ([24][O3SCF3]6). Yield: 73 mg (68%). 
1H NMR (400 MHz, acetone-d6): δ (ppm) = 8.72 (dd, 12H, 3JH-H = 5.28 Hz, 4JH-H = 1.56 
Hz, Hα), 8.62 (dd, 12H, Hβ), 6.29 (d, 12H, 3JH-H = 6.44 Hz, Har), 6.12 (d, 12H, Har), 3.04 
(sept, 6H, 3JH-H = 6.84 Hz, CH), 2.36 (s, 18H, CH3), 1.46 (d, 36H, CH3). 13C{1H} NMR 
(100 MHz, acetone-d6): δ (ppm) = 178.9, 170.5, 155.1, 145.6, 125.8, 120.6, 107.1, 105.0, 
99.9, 84.8, 83.9, 32.2, 22.5, 18.18. IR (cm-1): 1744(s), 1408(s), 1218(s), 1092(s), 1032(s), 
904(s), 797(s). Anal. Calc. for C120H108N12Cl6O30F18S6Ru6: C, 40.60; H, 3.01; N, 4.73. 
Found: C, 40.36; H, 3.17; N, 4.52%. 
 
 
[(η6-C6Me6)6Ru6(tpt)2(dhbq)3][O3SCF3]6 ([25][O3SCF3]6). Yield: 50 mg (47%). 1H 
NMR (400 MHz, acetone-d6): δ (ppm) = 8.85 (dd, 12H, 3JH-H = 5.12 Hz, 4JH-H = 1.48 Hz, 
Hα), 8.46 (dd, 12H, Hβ), 5.84 (s, 6H, Hq), 2.17 (s, 108H, CH3). 13C{1H} NMR (100 MHz, 
acetone-d6): δ (ppm) = 183.6, 169.4, 153.7, 144.1, 125.2, 105.3, 101.9, 93.7, 14.7. IR 
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(cm-1): 1748(s), 1388(s), 1221(s), 1092(s), 781(s). Anal. Calc. for 
C132H138N12O30F18S6Ru6: C, 45.12; H, 3.96; N, 4.78. Found: C, 45.54; H, 3.76; N, 4.59%. 
 
 
[(η6-C6Me6)6Ru6(tpt)2(dchq)3][O3SCF3]6 ([26][O3SCF3]6). Yield: 88 mg (79%). 1H 
NMR (400 MHz, acetoned6): δ (ppm) = 8.89 (dd, 12H, 3JH-H = 6.60 Hz, 4JH-H = 1.44 Hz, 
Hα), 8.44 (dd, 12H, Hβ), 2.20 (s, 108H, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ 
(ppm) = 177.4, 169.5, 153.6, 144.4, 125.5, 108.8, 106.1, 94.0, 14.8. IR (cm-1): 1742(s), 
1374(s), 1206(s), 1092(s), 849(s). Anal. Calc. for C132H132N12O30F18S6Cl6Ru6: C, 42.62; 
H, 3.58; N, 4.52. Found: C, 42.81; H, 3.25; N, 4.78%. 
 
 
7.2.7 Prisms with aromatic guest molecule, aromatic⊂23-26 
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General synthesis of [aromatic⊂23][O3SCF3]6
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Synthesis of [aromatic⊂23][O3SCF3]6. A mixture of [(η6-p-
iPrC6H4Me)2Ru2(dhbq)Cl2] (70 mg, 0.1 mmol) and AgO3SCF3 (54 mg, 0.2 mmol) in 
MeOH (20 mL) was stirred at room temperature for 2 h, then filtered. To the red filtrate 
was added tpt (21 mg, 0.07 mmol) and the aromatic molecule (pyrene 7.6 mg, 0.038 
mmol; fluoranthene 7 mg, 0.035 mmol; triphenylene 9.0 mg, 0.037 mmol; 
benzo[e]pyrene 9.5 mg, 0.038 mmol; coronene 12 mg, 0.036 mmol). The mixture was 
stirred at room temperature for 24 h, and the solvent removed in vacuo. The dark residue 
was taken up in CH2Cl2 (20 mL), and after filtration, the solution was concentrated (3 
mL) and Et2O was added to precipitate a red solid. 
 
 
[pyrene⊂23][O3SCF3]6. Yield: 85 mg (82%). 1H NMR (400 MHz, acetone-d6): δ (ppm) 
= 8.56 (dd, 12H, 3JH-H = 5.04 Hz, 4JH-H = 1.36 Hz, Hα), 8.04 (dd, 12H Hβ), 6.68 (s, 4H, 
Hg), 6.62 (d, 4H, 3JH-H = 7.44 Hz, Hg), 6.22 (d, 12H, 3JH-H = 6.24 Hz, Har), 6.20 (d, 2H, 
Hg), 6.17 (s, 6H, Hq), 6.00 (d, 12H, Har), 2.99 (sept, 6H, 3JH-H = 7.00 Hz, CH), 2.22 (s, 
18H, CH3), 1.39 (d, 36H, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 185.1, 
168.6, 144.3, 130.3, 127.9, 126.5, 125.1, 123.4, 104.9, 102.8, 100.2, 84.8, 83.1, 32.1, 
22.5, 18.1. IR (cm-1): 1638(s), 1617(s), 1524(s), 1377(m), 1259(s), 1159(m), 1030(m), 
636(s). Anal. Calc. for C136H124N12O30F18S6Ru6: C, 45.63; H, 3.49; N, 4.69. Found: C, 
45.93; H, 3.77; N, 4.53%. 
 
 
[fluoranthene⊂23][O3SCF3]6. Yield: 85 mg (81%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.54 (dd, 12H, 3JH-H = 5.12 Hz, 4JH-H = 1.48 Hz, Hα), 8.18 (dd, 12H Hβ), 6.88 (br, 
2H, Hg), 6.67 (d, 2H, 3JH-H = 7.80 Hz, Hg), 6.47 (d, 2H, 3JH-H = 6.60 Hz, Hg), 6.21 (d, 
12H, 3JH-H = 6.36 Hz, Har), 6.11 (s, 6H, Hq), 5.99 (d, 12H, Har), 5.35 (br, 2H, Hg), 5.23 
(br, 2H, Hg), 2.98 (sept, 6H, 3JH-H = 7.08 Hz, CH), 2.22 (s, 18H, CH3), 1.39 (d, 36H, 
CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.1, 168.2, 153.8, 143.5, 
134.7, 128.3, 126.7, 124.5, 121.5, 120.1, 117.0, 113.2, 104.0, 101.9, 99.3, 83.9, 82.2, 
31.2, 21.6, 17.2. IR (cm-1): 1716(s), 1524(m), 1435(m), 1363(s), 1221(s), 1092(m), 
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1032(m), 850(s). Anal. Calc. for C136H124N12O30F18S6Ru6: C, 46.05; H, 3.52; N, 4.74. 
Found: C, 46.21; H, 3.85; N, 4.63%. 
 
 
[triphenylene⊂23][O3SCF3]6. Yield: 95 mg (72%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.47 (d, 12H, 3JH-H = 6.08 Hz, Hα), 8.10 (d, 12H, Hβ), 7.62 (dd, 6H, 3JH-H = 2.72 
Hz, Hg), 6.20 (d, 12H, 3JH-H = 6.24 Hz, Har), 6.16 (s, 6H, Hq), 5.98 (d, 12H, Har), 5.35 (dd, 
6H, Hg), 2.96 (sept, 6H, 3JH-H = 6.80 Hz, CH), 2.21 (s, 18H, CH3), 1.38 (d, 36H, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.6, 168.2, 153.9, 143.5, 128.6, 
127.0, 125.0, 123.4, 104.5, 102.4, 99.7, 84.4, 82.7, 31.6, 22.1, 17.7. IR (cm-1): 1638(s), 
1617(s), 1524(s), 1377(s), 1259(s), 1162(m), 1031(s), 638(s). Anal. Calc. for 
C138H126N12O30F18S6Ru6: C, 45.97; H, 3.52; N, 4.66. Found: C, 45.81; H, 3.88; N, 4.45%. 
 
 
[benzo[e]pyrene⊂23][O3SCF3]6. Yield: 90 mg (68%). 1H NMR (400 MHz, acetone-d6): 
δ (ppm) = 8.48 (d, 12H, 3JH-H = 5.20 Hz, Hα), 7.90 (d, 2H, 3JH-H = 8.00 Hz, Hg), 7.88 (d, 
12H, Hβ), 7.82 (dd, 4H, 3JH-H = 5.96 Hz, Hg), 7.39 (s, 2H, Hg), 6.27 (s, 6H, Hq), 6.20 (d, 
12H, 3JH-H = 6.24 Hz, Har), 5.99 (d, 12H, Har), 5.75 (dd, 2H, 3JH-H = 7.48 Hz, Hg), 5.50 
(dd, 2H, Hg), 2.97 (sept, 6H, 3JH-H = 6.92 Hz, CH), 2.21 (s, 18H, CH3), 1.40 (d, 36H, 
CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.3, 167.4, 153.4, 142.7, 
128.2, 126.3, 124.2, 122.4, 120.4, 119.7, 118.3, 113.4, 106.7, 104.1, 102.0, 99.2, 83.9, 
82.3, 31.2, 21.6, 17.2. IR (cm-1): 1634(s), 1619(s), 1524(s), 1375(s), 1225(m), 1160(m), 
1031(s), 638(s). Anal. Calc. for C140H126N12O30F18S6Ru6: C, 46.74; H, 3.53; N, 4.67. 
Found: C, 46.72; H, 3.80; N, 4.42%.  
 
 
[coronene⊂23][O3SCF3]6. Yield 95 mg (70%). 1H NMR (200 MHz, acetone-d6): δ 
(ppm) = 8.48 (dd, 12H, 3JH-H = 5.50 Hz, 4JH-H = 1.48 Hz, Hα), 7.50 (s, 12H, Hg), 7.20 (dd, 
12H, Hβ), 6.53 (s, 6H, Hq), 6.19 (d, 12H, 3JH-H = 6.60 Hz, Har), 5.97 (d, 12H, Har), 3.03 
(sept, 6H, 3JH-H = 6.96 Hz, CH), 2.21 (s, 18H, CH3), 1.40 (d, 36H, CH3). 13C {1H} NMR 
(100 MHz, acetone-d6): δ (ppm) = 184.5, 166.3, 153.5, 141.8, 127.6, 126.0, 123.5, 120.8, 
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104.1, 102.3, 99.1, 83.8, 82.4, 31.2, 21.6, 17.2. IR (cm-1): 1638(s), 1617(s), 1522(s), 
1377(s), 1259(s), 1225(m), 1161(s), 1030(s), 638(s). Anal. Calc. for 
C144H126N12O30F18S6Ru6: C, 51.03; H, 3.74; N, 4.96. Found: C, 51.09; H, 3.83; N, 4.29%. 
 
General synthesis of [aromatic⊂24][O3SCF3]6
These carceplex systems are prepared in the same procedure as described above 
for [aromatic⊂23][O3SCF3]6 using [(η6-p-iPrC6H4Me)2Ru2(dchq)Cl2] (70mg, 0.09 mmol), 
AgO3SCF3 (49 mg, 0.19 mmol), tpt (20 mg, 0.06 mmol), and the aromatic molecule 
(fluoranthene 7 mg, 0.03 mmol; triphenylene 8 mg, 0.03 mmol). 
 
 
[fluoranthene⊂24][O3SCF3]6. Yield: 87 mg (75%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.59 (m, 24H, Hα, Hβ), 6.81 (m, 2H, Hg), 6.57 (m, 2H, Hg), 6.43 (m, 2H, Hg), 
6.30 (d, 8H, 3JH-H = 6.33 Hz, Har), 6.12 (d, 12H, 3JH-H = 5.49 Hz, Har), 5.32 (m, 2H, Hg), 
5.12 (m, 2H, Hg), 3.05 (sept, 6H, 3JH-H = 6.94 Hz, CH), 2.35 (s, 18H, CH3), 1.46 (d, 36H, 
3JH-H = 6.92 Hz, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 177.9, 153.9, 
144.3, 135.8, 129.8, 127.5, 127.2, 125.9, 124.0, 122.5, 120.9, 120.8, 120.7, 106.5, 104.4, 
99.3, 84.1, 83.1, 31.5, 21.7, 17.4. IR (cm-1): 1618(w), 1574(w), 1500(vs), 1373(s), 
1313(w), 1258(s), 1224(m), 1159(m), 1057(w), 1030(s), 867(w), 810(w), 638(s). Anal. 
Calc. for C140H126N12O30F18S6Ru6: C, 43.51; H, 3.17; N, 4.48. Found: C, 36.46; H, 3.25; 
N, 4.49%. 
 
 
[triphenylene⊂24][O3SCF3]6. Yield: 80 mg (68%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.47 (d, 12H, 3JH-H = 6.60 Hz, Hα), 8.22 (d, 12H, Hβ), 7.63 (dd, 6H, 3JH-H = 6.08 
Hz, Hg), 6.31 (d, 12H, 3JH-H = 6.36 Hz, Har), 6.12 (d, 12H, Har), 5.14 (dd, 6H, Hg), 3.03 
(sept, 6H, 3JH-H = 7.12 Hz, CH), 2.32 (s, 18H, CH3), 1.46 (d, 36H, CH3). 13C{1H} NMR 
(100 MHz, acetone-d6): δ (ppm) = 177.7, 167.9, 153.3, 143.4, 128.4, 126.0, 125.0, 123.3, 
120.5, 106.7, 104.4, 99.4, 84.1, 83.0, 31.5, 21.6, 17.3. IR (cm-1): 1723(s), 1504(s), 
1414(s), 1227(s), 1152(m), 1032(m), 1092(s), 901(s), 829(s). Anal. Calc. for 
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C138H120N12O30F18S6Cl6Ru6: C, 43.85; H, 3.20; N, 4.45. Found: C,43.45; H, 3.61; N, 
4.25%. 
 
 
 
General synthesis of [aromatic⊂25][O3SCF3]6  
These carceplex systems are prepared in the same procedure as described above 
for [aromatic⊂23][O3SCF3]6 using [(η6-C6Me6)2Ru2(dhbq)Cl2] (60 mg, 0.08 mmol), 
AgO3SCF3 (43 mg, 0.016 mmol), tpt (17 mg, 0.05 mmol), and the aromatic molecule 
(fluoranthene 6 mg, 0.03 mmol; triphenylene 6 mg, 0.03 mmol). 
 
 
[fluoranthene⊂25][O3SCF3]6. Yield 55 mg (51%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.37 (m, 24H, Hα, Hβ), 6.85 (dd, 2H, 3JH-H = 3.15, 5.39 Hz, Hg), 6.58 (d, 2H, 3JH-
H = 8.10 Hz, Hg), 6.47 (d, 2H, 3JH-H = 6.60 Hz, Hg), 6.04 (s, 6H, Hq), 5.36 (dd, 2H, 3JH-H = 
7.51 Hz, Hg), 5.14 (m, 2H, Hg), 2.16 (s, 108H, CH3). 13C{1H} NMR (100 MHz, acetone-
d6): δ (ppm) = 184.3, 153.7, 144.1, 138.3, 135.3, 134.5, 127.3, 127.2, 125.6, 123.8, 122.1, 
120.7, 120.6, 102.5, 94.3, 15.2. IR (cm-1): 1628(w), 1518(vs), 1374(s), 1257(s), 1157(w), 
1031(m), 811(w), 638(m). Anal. Calc. for C148H148Cl6N12O30F18S6Ru6 ⋅4H2O: C, 44.44; 
H, 3.93; N, 4.20. Found: C, 44.47; H, 4.41; N, 4.32%.  
 
 
[triphenylene⊂25][O3SCF3]6. Yield: 50 mg (49%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.30 (dd, 12H, 3JH-H = 5.08 Hz, Hα), 8.20 (dd, 12H, Hβ), 7.59 (dd, 6H, 3JH-H = 
4.68 Hz, Hg), 6.14 (s, 6H, Hq), 5.32 (dd, 6H, Hg), 2.15 (s, 108H, CH3). 13C{1H} NMR 
(100 MHz, acetone-d6): δ (ppm) = 184.6, 169.2, 153.5, 144.5, 128.4, 126.3, 125.9, 123.2, 
108.6, 103.5, 94.6, 15.5. IR (cm-1): 1759(s), 1523(m), 1448(s), 1224(s), 1032(m), 904(s). 
Anal. Calc. for C150H150N12O30F18S6Ru6: C, 48.15; H, 4.05; N, 4.49. Found: C, 48.36; H, 
4.06; N, 4.09%. 
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General synthesis of [aromatic⊂26][O3SCF3]6
These carceplex systems are prepared in the same procedure as described above 
for [aromatic⊂23][O3SCF3]6 using [(η6-C6Me6)2Ru2(dchq)Cl2] (60 mg, 0.07 mmol), 
AgO3SCF3 (39 mg, 0.015 mmol), tpt (16 mg, 0.05 mmol), and aromatic molecules 
(fluoranthene 6 mg, 0.03 mmol; triphenylene 6 mg, 0.03 mmol).  
 
 
[fluoranthene⊂26][O3SCF3]6. Yield: 77 mg (77%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.36 (m, 24H, Hα, Hβ), 6.86 (m, 2H, Hg), 6.50 (m, 4H, Hg), 5.38 (m, 2H, Hg), 
5.08 (m, 2H, Hg), 2.20 (s, 108H, CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 
178.1, 169.0, 153.8, 144.6, 127.3, 127.2, 126.4, 124.2, 122.7, 121.1, 121.0, 107.3, 95.1, 
15.8. IR (cm-1): 1623(br), 1574(w), 1500(vs), 1372(s), 1263(s), 1152(m), 1031(s), 
866(w), 811(w), 637(m). Anal. Calc. for C148H142Cl6N12O30F18S6Ru6: C, 45.32; H, 3.65; 
N, 4.29. Found: C, 37.93; H, 3.45; N, 3.64%.  
 
 
[triphenylene⊂26][O3SCF3]6. Yield: 55 mg (56%). 1H NMR (400 MHz, acetone-d6): δ 
(ppm) = 8.33 (dd, 12H, 3JH-H = 5.00 Hz, Hα), 8.27 (dd, 12H, Hβ), 7.58 (dd, 6H, 3JH-H = 
6.12 Hz, Hg), 5.12 (dd, 6H, Hg), 2.19 (s, 108H, CH3). 13C{1H} NMR (100 MHz, acetone-
d6): δ (ppm) = 177.1, 167.6, 163.7, 152.4, 143.2, 126.0, 125.5, 123.2, 110.9, 106.4, 94.1, 
14.8. IR (cm-1): 1709(s), 1411(m), 1217(s), 1093(s), 1032(m), 906(s), 787(s). Anal. Calc. 
for C150H144N12O30F18S6Cl6Ru6: C, 45.63; H, 3.68; N, 4.26. Found: C, 45.32; H, 3.76; N, 
4.21%. 
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7.2.8 Prisms with functionalized pyrenyl derivatives, a-i⊂23 
 
 
 
General synthesis of [a–i⊂23][O3SCF3]6 
[(η6-p-iPrC6H4Me)2Ru2(dhbq)Cl2] (50 mg, 0.0736 mmol) and AgO3SCF3 (38 mg, 
0.147 mmol) was stirred in MeOH (30 mL) for 2 h, thereafter the solution was filtered 
into a suspension of tpt (15 mg, 0.049 mmol) and pyrenyl (1-pyrenebutanol 6.8 mg, 0.025 
mmol; 1-pyrenemethyl butanoate 7.5 mg, 0.025 mmol; 1-pyrenebutyric acid 7.1 mg, 
0.025 mmol; 1-pyrenemethylamine 6.7 mg, 0.025 mmol; N-hexadecylpyrene-1-
sulfonamide 12.6 mg, 0.025 mmol; 1-(4,6-dichloro-1,3,5-triazin-2yl)pyrene 8.8 mg, 
0.025 mmol; pyrenyl ethacrynic amide 12.7 mg, 0.025 mmol; 2-(pyren-1-
ylmethylcarbamoyl) phenyl acetate 9.7 mg, 0.025 mmol) in MeOH (10 mL). The mixture 
was stirred at RT for 18 h. The MeOH was removed under reduced pressure and then the 
product re-dissolved in CH2Cl2 before being filtered. The filtrate was reduced to about 5 
mL and the product precipitated with Et2O and collected by filtration as a red powder. 
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[a⊂23][O3SCF3]6. Yield: 68 mg (77%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.58 
(d, 12H, 3JH-H = 6.39 Hz, Hα), 8.07 (br, 12H, Hβ), 7.24 (d, 1H, 3JH-H = 4.43 Hz, Hg), 7.11 
(m, 1H, Hg), 6.99 (br, 1H, Hg), 6.91 (br, 1H, Hg), 6.57 (br, 1H, Hg), 6.34(br, 1H, Hg), 6.22 
(d, 12H, 3JH-H = 6.24 Hz, Har), 6.18 (s, 6H, Hq), 6.13 (br, 2H, Hg), 6.00 (d, 12H, Har), 5.85 
(br, 1H, Hg), 2.98 (sept, 6H, 3JH-H = 6.91 Hz, CH), 2.62 (br, 2H, Hg), 2.50 (br, 2H, Hg), 
2.22 (s, 18H, CH3), 1.62 (br, 2H, Hg), 1.39 (d, 36H, CH3). 13C{1H} NMR (100 MHz, 
acetone-d6): δ (ppm) = 184.3, 167.9, 154.0, 143.5, 124.3, 104.2, 102.1, 99.4, 84.0, 82.4, 
31.3, 21.7, 17.3. IR (cm-1): 1524(s), 1377(s), 1258(s), 1224(w), 1159(w), 1030(m), 
811(w), 638(w). MS (ESI-MS) m/z: 1062.42 [a⊂23 + (O3SCF3)3]3+, 759.32 [a⊂23 + 
(O3SCF3)2]4+. UV-visible (MeOH): λmax 495 (45500), 351 (42300), 304 (81000), 281 
(57500), 271 (54300) nm. 
 
 
[b⊂23][O3SCF3]6. Yield: 78 mg (88%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.58 
(d, 12H, 3JH-H = 6.4Hz Hα), 8.06 (br, 12H, Hβ), 7.03 (d, 1H, 3JH-H = 8.8 Hz, Hg), 6.95 (d, 
1H, 3JH-H = 6.8 Hz, Hg), 6.87 (d, 1H, 3JH-H = 8.4 Hz, Hg), 6.52 (d, 1H, 3JH-H = 8.8 Hz, Hg), 
6.22 (d, 12H, 3JH-H = 6.4 Hz, Har), 6.18 (s, 6H, Hq), 6.00 (d, 12H, Har), 3.76 (d, 2H, 3JH-H = 
5.2 Hz, Hg), 2.98 (sept, 6H, 3JH-H = 6.8 Hz, CH), 2.52 (t, 2H 3JH-H = 7.2 Hz, Hg), 2.22 (s, 
18H, CH3), 1.63 (m, 2H, Hg), 1.47 (m, 2H, Hg), 1.39 (d, 36H, 3JH-H = 7.2 Hz, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 185.1, 168.6, 154.8, 144.3, 137.5, 
130.7, 130.1, 128.9, 128.4, 128.0, 127.6, 127.1, 126.6, 126.6, 125.7, 125.4, 125.4, 125.1, 
124.0, 123.8, 123.7, 123.2, 120.8, 105.0, 102.9, 100.2, 84.8, 83.1, 62.3, 33.7, 33.2, 32.1, 
22.5, 18.1. IR (cm-1): 1523(s), 1377(s), 1258(s), 1224(w), 1159(w), 1030(m), 811(w), 
638(w). MS (ESI-MS) m/z: 1057.79 [b⊂23 + (O3SCF3)3]3+, 756.09 [b⊂23 + 
(O3SCF3)2]4+. UV-visible (MeOH): λmax 493 (44800), 342 (47300), 308 (80800), 275 
(64300). 
 
 
[c⊂23][O3SCF3]6. Yield: 49 mg (56%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.59 
(br, 12H, Hα), 8.22 (br, 12H, Hβ), 6.20 (d, 12H, 3JH-H = 6.21 Hz, Har), 6.14 (s, 6H, Hq), 
5.99 (d, 12H, Har), 2.98 (sept, 6H, 3JH-H = 6.96 Hz, CH), 2.22 (s, 18H, CH3), 1.40 (d, 36H, 
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CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 185.2, 154.0, 124.4, 104.1, 
101.9, 99.2, 83.8, 82.3, 31.4, 21.6, 17.3. IR (cm-1): 1524(s), 1377(s), 1259(s), 1225(w), 
1161(w), 1031(m), 812(w), 639(w). MS (ESI-MS) m/z: 1043.41 [c⊂23 + (O3SCF3)3]3+, 
745.07 [c⊂23 + (O3SCF3)2]4+. UV-visible (MeOH): λmax 494 (43100), 341 (54300), 309 
(83200), 275 (73200) nm.  
 
 
[d⊂23][O3SCF3]6. Yield: 64 mg (72%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.58 
(d, 12H, 3JH-H = 6.54 Hz, Hα), 8.10 (br, 12H, Hβ), 7.14 (d, 1H, 3JH-H = 9.11 Hz, Hg), 6.98 
(d, 1H, 3JH-H = 7.42 Hz, Hg), 6.92 (d, 1H, 3JH-H = 8.88 Hz, Hg), 6.33 (dd, 1H, 3JH-H = 7.41 
Hz, Hg), 6.26 (br, 1H, Hg), 6.22 (d, 12H, 3JH-H = 6.31 Hz, Har), 6.19 (m, 1H, Hg), 6.16 (s, 
6H, Hq), 6.08 (d, 1H, 3JH-H = 7.56 Hz, Hg), 6.00 (d, 12H, 3JH-H = 6.31 Hz, Har), 5.85 (d, 
1H, 3JH-H = 7.53 Hz, Hg), 3.80 (s, 3H, Hg), 2.98 (sept, 6H, 3JH-H = 6.94 Hz, CH), 2.54 (m, 
4H, Hg), 2.23 (s, 18H, CH3), 1.67 (m, 2H, Hg), 1.40 (d, 36H, 3JH-H = 6.94 Hz, CH3). 
13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 185.2, 183.1, 168.8, 154.9, 144.4, 
128.6, 127.9, 127.4, 126.7, 126.5, 125.9, 125.5, 125.3, 125.2, 124.1, 123.6, 123.2, 123.1, 
120.9, 105.1, 102.9, 84.8, 83.3, 52.3, 34.3, 32.2, 26.9, 22.6, 18.2. IR (cm-1): 1731(w), 
1523(vs), 1376(s), 1258(s), 1159(w), 1057(w), 1030(m), 811(w), 638(m). MS (ESI-MS) 
m/z: 1067.10 [d⊂23 + (O3SCF3)3]3+, 1674.70 [d⊂23 + (O3SCF3)4]2+. UV-visible 
(CH2Cl2): λmax 494 (46100), 342 (83800), 298 (113100), 275 (147200), 242 (260800), 
211 (274300) nm. 
 
 
[e⊂23][O3SCF3]6. Yield: 59 mg (65%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.54 
(br, 12H, Hα), 8.00 (br, 12H, Hβ), 6.20 (d, 12H, 3JH-H = 6.02 Hz, Har), 6.18 (s, 6H, Hq), 
5.98 (d, 12H, Har), 2.97 (sept, 6H, 3JH-H = 6.68 Hz, CH), 2.21 (s, 18H, CH3), 1.39 (d, 36H, 
CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.4, 154.1, 124.3, 104.3, 
102.2, 99.3, 83.9, 82.4, 31.3, 21.7, 17.3. IR (cm-1): 1523(s), 1377(s), 1258(s), 1224(w), 
1159(w), 1030(m), 811(w), 638(w). MS (ESI-MS) m/z: 1081.40 [e⊂23 + (O3SCF3)3]3+, 
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773.81 [e⊂23 + (O3SCF3)2]4+. UV-visible (MeOH): λmax 491 (49200), 373 (51000), 300 
(99300), 271 (67300) nm. 
 
 
[f⊂23][O3SCF3]6. Yield: 61 mg (65%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.63 
(br, 12H, Hα), 8.42 (br, 12H, Hβ), 6.22 (d, 12H, 3JH-H = 6.46 Hz, Har), 6.02 (s, 6H, Hq), 
6.01 (d, 12H, Har), 2.99 (sept, 6H, 3JH-H = 6.93 Hz, CH), 2.25 (s, 18H, CH3), 1.40 (d, 36H, 
CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.3, 154.3, 124.8, 104.2, 
102.0, 99.3, 83.9, 82.4, 31.4, 21.8, 17.5. IR (cm-1): 1523(s), 1377(s), 1258(s), 1224(w), 
1158(w), 1030(m), 811(w), 638(w). MS (ESI-MS) m/z: 1134.48 [f⊂23 + (O3SCF3)3]3+, 
813.63 [f⊂23 + (O3SCF3)2]4+. UV-visible (MeOH): λmax 492 (38700), 351 (41100), 301 
(76400), 281 (65800) nm.  
 
 
[g⊂23][O3SCF3]6. Yield: 75 mg (78%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.56 
(br, 12H, Hα), 8.36 (br, 2H, Hg), 8.00 (br, 12H, Hβ), 7.56 (br, 2H, Hg), 7.23 (br, 1H, Hg), 
7.09 (br, 1H, Hg), 6.80 (br, 1H, Hg), 6.20 (d, 12H, 3JH-H = 6.08 Hz, Har), 6.18 (s, 6H, Hq), 
6.05 (br, 2H, Hg), 5.99 (d, 12H, Har), 5.83 (br, 2H, Hg), 5.79 (br, 2H, Hg), 5.18 (s, 2H, 
Hg), 4.52 (br, 2H, Hg), 2.98 (sept, 6H, 3JH-H = 6.93 Hz, CH), 2.53 (q, 2H, 3JH-H = 7.07 Hz, 
Hg), 2.23 (s, 18H, CH3), 1.39 (d, 36H, CH3), 1.21 (t, 3H, Hg). 13C{1H} NMR (100 MHz, 
acetone-d6): δ (ppm) = 184.3, 167.6, 154.0, 124.3, 104.2, 102.0, 99.2, 83.9, 82.5, 31.3, 
21.7, 17.3. IR (cm-1): 1524(s), 1377(s), 1259(s), 1225(w), 1159(w), 1031(m), 811(w), 
638(w). MS (ESI-MS) m/z: 1138.42 [g⊂23 + (O3SCF3)3]3+, 816.32 [g⊂23 + 
(O3SCF3)2]4+. UV-visible (MeOH): λmax 492 (44700), 341 (56300), 309 (83900), 275 
(76000) nm. 
 
 
[h⊂23][O3SCF3]6. Yield: 66 mg (72%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 9.12 
(br, 1H, Hg), 8.56 (br, 12H, Hα), 7.97 (br, 12H, Hβ), 7.73 (br, 2H, Hg), 7.39 (br, 2H, Hg), 
7.25 (br, 1H, Hg), 6.95 (br, 2H, Hg), 6.19 (br, 19H, Har, Hq, Hg), 5.99 (br, 13H, Har, Hg), 
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4.79 (br, 2H, Hg), 2.98 (sept, 6H, 3JH-H = 6.64 Hz, CH), 2.26 (s, 18H, CH3), 1.41 (d, 36H, 
CH3). 13C{1H} NMR (100 MHz, acetone-d6): δ (ppm) = 184.2, 167.6, 153.9, 124.3, 
104.1, 101.9, 83.9, 82.5, 65.3, 31.3, 21.7, 17.3, 14.8. IR (cm-1): 1524(s), 1377(s), 1258(s), 
1224(w), 1158(w), 1030(m), 811(w), 637(w). MS (ESI-MS) m/z: 1083.46 [h⊂23 – 
CH3CO + (O3SCF3)3]3+, 775.34 [h⊂23 – CH3CO + (O3SCF3)2]4+. UV-visible (MeOH): 
λmax 495 (43400), 350 (45700), 342 (45600), 306 (81200), 281 (58500), 276 (57600) nm. 
 
 
[i⊂23][O3SCF3]6. Yield 78 mg (85%). 1H NMR (400 MHz acetone-d6): δ (ppm) = 8.56 
(br, 12H, Hα), 8.03 (br, 12H, Hβ), 7.08 (br, 1H, Hg), 6.79 (br, 2H, Hg), 6.38 (br, 4H, Hq), 
6.21 (d, 12H, 3JH-H = 6.11 Hz, Har), 6.21 (br, 2H, Hq), 6.06 (br, 1H, Hg), 5.99 (d, 12H, 
Har), 5.80 (br, 2H, Hg), 5.54 (br, 1H, Hg), 5.06 (br, 2H, Hg), 2.98 (sept, 6H, 3JH-H = 6.89 
Hz, CH), 2.20 (s, 18H, CH3), 1.74 (s, 12H, Hg), 1.38 (d, 36H, CH3). 13C{1H} NMR (100 
MHz, acetone-d6): δ (ppm) = 185.0, 154.9, 125.2, 105.0, 100.2, 84.8, 83.0, 32.0, 22.5, 
18.1. IR (cm-1) : 1524(s), 1377(s), 1259(s), 1161(w), 1030(m), 811(w), 638(w). MS (ESI-
MS) m/z: 1705.13 [i⊂23 + (O3SCF3)4]2+, 1088.44 [i⊂23 + (O3SCF3)3]3+. UV-visible 
(MeOH): λmax 491 (50600), 383 (90200), 362 (68700), 345 (47100), 301 (88300), 290 
(106000), 278 (71500) nm. 
 
 
Cytotoxicity study of supramolecular prism encapsulating functionalized pyrenyl 
derivatives 
Human A2780 ovarian carcinoma cells were obtained from the European Centre 
of Cell Cultures (ECACC, Salisbury, UK) and maintained in culture as described by the 
provider. The cells were routinely grown in RPMI 1640 medium with GlutaMAX™ 
containing 5% fetal calf serum (FCS) and antibiotics (penicillin and ciproxin) at 37 °C 
and 5% CO2. For the evaluation of growth inhibition, the cells were seeded in 96-well 
plates (25x103 cells per well) and grown for 24 h in complete medium. Complexes were 
added to the required concentration and added to the cell culture for 72 h incubation. 
Solutions of the compounds were applied by diluting a freshly prepared stock solution of 
the corresponding compound in aqueous RPMI medium with GlutaMAX™ (20 mM). 
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Following drug exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) was added to the cells at a final concentration of 0.25 mg/ml and 
incubated for 2 h, then the culture medium was aspirated and the violet formazan 
(artificial chromogenic precipitate of the reduction of tetrazolium salts by 
dehydrogenases and reductases) dissolved in DMSO. The optical density of each well 
(96-well plates) was quantified three times in tetraplicates at 540 nm using a multiwell 
plate reader (iEMS Reader MF, Labsystems, US), and the percentage of surviving cells 
was calculated from the ratio of absorbance of treated to untreated cells. The IC50 values 
for the inhibition of cell growth were determined by fitting the plot of the logarithmic 
percentage of surviving cells against the logarithm of the drug concentration using a 
linear regression function. The median value and the median absolute deviation were 
obtained from the Excel™ software (Microsoft ™). 
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1 X-ray crystallography structures 
Crystallographic data of solved structures in this thesis can be retrieved from the 
Cambridge Crystallographic Data Centre (CCDC). Given in the table below is the 
compound number with corresponding CCDC number. 
 
Compound CCDC number Found on page Found in reference 
5 CCDC-723508 28 [173] 
[17][ O3SCF3]4 CCDC-721012 47 [155] 
[22][ O3SCF3]4 CCDC-721013 49 [155] 
[pyrene⊂23][O3SCF3]6 CCDC-685450 72 [118] 
[benzo[e]pyrene⊂23][O3SCF3]6 CCDC-662926 72 [118] 
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